<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://embryology.med.unsw.edu.au/embryology/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Z3374116</id>
	<title>Embryology - User contributions [en-gb]</title>
	<link rel="self" type="application/atom+xml" href="https://embryology.med.unsw.edu.au/embryology/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Z3374116"/>
	<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Special:Contributions/Z3374116"/>
	<updated>2026-11-19T01:20:13Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.39.10</generator>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209655</id>
		<title>User:Z3374116</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209655"/>
		<updated>2015-10-29T14:57:21Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 17:18, 5 August 2015 (AEST) Note your student number is already blue, as you have been previously enrolled in this course.&lt;br /&gt;
&lt;br /&gt;
Resource Investigator&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 13:45, 7 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:12, 14 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:08, 21 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:03, 4 September 2015 (AEST) - Left early for Funeral&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:16, 11 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:26, 18 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:44, 25 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:13, 9 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:35, 16 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 23 October 2015 - Attendance did not log properly (heart formation lab where you went though our projects and said it was too pink)&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 1==&lt;br /&gt;
&lt;br /&gt;
'''Article 1'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26260201&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This article was written in aims to evaluate a prospectively implemented clinical algorithm which served in the early identifications of Ectopic pregnancy (EP) and Heterotopic pregnancy (HP) after use of assisted reproductive technologies (In-vitro fertilization). The data used in this research were patients who all received in-vitro fertilization or other methods of Assisted reproductive technology from between January 1995 to June 2013. &lt;br /&gt;
&lt;br /&gt;
The early pregnancy stage was monitored using clinical algorithms where all pregnancies were screened using Human chorionic gonadotropin (hCG) levels and any reported symptoms during pregnancy as well as use of ultrasound evaluations where hCG levels were abnormal or patient reported any pains.&lt;br /&gt;
&lt;br /&gt;
The research found that within the 3904 pregnancies included in the data, the incidence of Ectopic and Heterotopic pregnancies were 0.77% and 0.46% respectively. The clinical algorithm managed to detect and select 96.7% of the 0.77% diagnosed with EP as well as 83.3% of the 0.46% diagnosed with HP leading to earlier treatment and resolution of the problem. These results showed the effectiveness of the developed clinical algorithm in the early identification and prompt intervention of EP and HP bypassing the catastrophic morbidity associated with delayed diagnosis&lt;br /&gt;
&lt;br /&gt;
'''Article 2'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;24939956&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
	The article researched the effects of different levels of progesterone on the day of human gonadotropin administration in the live birth delivery rates during in-vitro fertilization. Previous researches have shown that the presence of late follicular phase progesterone is essential for follicular development, ovulation and endometrial receptivity. Studies were carried out on 2723 cycles performed in patients aged between 19 ~35 years of age and undergoing controlled ovarian stimulation.&lt;br /&gt;
&lt;br /&gt;
	The patients underwent ovarian stimulation using a gonadotropin releasing hormone antagonist for pituitary down-regulation and then final oocyte maturation was triggered using hCG 36h before oocyte retrieval. On the day of hCG administration, progesterone evaluation was performed and live birth delivery rates were compared at regular progesterone intervals.&lt;br /&gt;
&lt;br /&gt;
	The study found that live birth rates were significantly lower in patients with bow low (&amp;lt;0.5 ng/ml) and high (&amp;gt;1.5 ng/ml) late follicular progesterone levels.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:09, 4 September 2015 (AEST) These are good summaries of the 2 papers with correct reference format. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 2 ==&lt;br /&gt;
&lt;br /&gt;
[[File:Biopsy of Morula Stage Embryo.png|700px]]&lt;br /&gt;
&lt;br /&gt;
'''Biopsy of a Morula Stage Embryo'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25191937&amp;lt;/pubmed&amp;gt;|[http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106433]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:10, 4 September 2015 (AEST) Image uploaded correctly with reference, copyright and student template. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 3 ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26246873&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:11, 4 September 2015 (AEST) These 3 references relate to your project topic. It would have been good to include even just a single sentence explaining why you selected these 3. (4/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 4 - Quiz ==&lt;br /&gt;
&lt;br /&gt;
=== Mesoderm Development ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Cells which migrate from '''somites''' form: &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Respiratory System&lt;br /&gt;
- Smooth Muscles&lt;br /&gt;
- Digestive System&lt;br /&gt;
+ Skeletal Muscles&lt;br /&gt;
- Reproductive System&lt;br /&gt;
|| '''Somites arise from the Paraxial Mesoderm and give rise to skeletal muscles as well as other musculoskeletal structures'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Fertilization ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Which of the following statements are '''INCORRECT''' regarding Implantation? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Implantation commences at day 6 ~ 7&lt;br /&gt;
+ The blastocyst rolls along the uterine wall to align the inner cell mass furthest from the uterine epithelium&lt;br /&gt;
- Implantation is the process in which a blastocyst enters the uterine wall&lt;br /&gt;
- A coagulation plug forms where the blastocyst has entered the uterine wall&lt;br /&gt;
|| '''The blastocyst initially rolls down the uterine walls aligning the inner cell mass to be closest to the uterine epithelium before implantation occurs. After the blastocyst has entered the Uterine wall, a coagulation plug forms at the site of implantation'''&lt;br /&gt;
&lt;br /&gt;
{At which of the following layers does Implantation occur? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Myometrium&lt;br /&gt;
- Spongy layer of Endometrium&lt;br /&gt;
- Perimetrium&lt;br /&gt;
+ Compact layer of Endometrium&lt;br /&gt;
- Implantation layer of Endometrium&lt;br /&gt;
|| '''Implantation occurs in the Compact layer of Endometrium containing  dense stromal cells, uterine gland necks and capillaries of spiral arteries'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:12, 4 September 2015 (AEST) 3 questions here please. I will assess after the lab today.&lt;br /&gt;
&lt;br /&gt;
[[ANAT2341 Student 2015 Quiz Questions]]&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 5 ==&lt;br /&gt;
&lt;br /&gt;
'''What is the difference between Gastroschisis and Omphalocele?'''&lt;br /&gt;
&lt;br /&gt;
Omphalocele is fetal defect (occurring 1 in every 4000 births) which is defined as the herniation of the abdominal viscera into the umbilical cord. In this abdominal wall defect, internal abdominal organs such as the intestines, liver protrude outside of the belly via the belly button where the organs are covered by a thin, opaque sac which separates the internal organs with the fluids in the amniotic sac during pregnancy. The occurrence of Omphalocele is due to the incorrect or incomplete development of the muscles of the abdominal wall. &lt;br /&gt;
&lt;br /&gt;
Gastroschisis is a defect which is thought to have been caused due to the interruption of blood supply to the developing abdominal wall from the omphalomesenteric duct artery in the 8th week of gestation. Unlike Omphalocele occurring from the belly button, it is characterized by an extra-umbilical herniation of internal abdominal organs at the junction of umbilicus and normal skin (beside the belly button) and not enclosed in visceral peritoneum. &lt;br /&gt;
&lt;br /&gt;
Omphalocele develops in the 9th week of development when the intestines do not re-enter the body cavity whereas Gastroschisis arises within the 6th ~ 7th week of development when the abdominal wall muscles of the baby do not develop properly&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''&amp;lt;pubmed&amp;gt;2932813&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;12130917&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;15305094&amp;lt;/pubmed&amp;gt;'''&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 7==&lt;br /&gt;
'''1. Identify and write a brief description of the findings of a recent research paper on development of one of the endocrine organs covered in today's practical.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''2. Identify the embryonic layers and tissues that contribute to the developing teeth.'''&lt;br /&gt;
&lt;br /&gt;
Tooth development (Odontogenesis) begins in the 6th week of embryonic development and is made up of ectoderm, mesoderm and neural crest ectomesenchyme&lt;br /&gt;
&lt;br /&gt;
-	'''Ameloblasts''': derived from the epithelium of ectoderm cells from the 1st pharyngeal arch which produces the enamel. Enamel covers the crown of the tooth and are only found to be present during the process of odontogenesis&lt;br /&gt;
&lt;br /&gt;
-	'''Odontoblasts''': ectomesenchymal cells derived from the neural crest. These cells begin by forming the predentin which later hardens to become dentin&lt;br /&gt;
&lt;br /&gt;
==Peer Reviews==&lt;br /&gt;
&lt;br /&gt;
'''Group 1'''&lt;br /&gt;
&lt;br /&gt;
From first glance of the page, just by looking at the contents table found at the top of the wikipage, I can already see that all the sections have been planned and well thought out with the appropriate subheadings and sub-subheadings which makes the page a lot easier to navigate if I were to be searching for something in particular on the topic ‘Three Person Embryo’&lt;br /&gt;
&lt;br /&gt;
The introduction is short and concise with the appropriate description of what the topic is about, adding the YouTube video in your introduction was a great touch (props to you for asking the maker permission to re-use as it’s under the YouTube Standard License) however I think this section could be improved by maybe addressing the key points that the wiki page will be covering&lt;br /&gt;
&lt;br /&gt;
It’s great to see some history behind the development and progression of ‘Mitochondrial’ Donation throughout the years!! Is there any more history regarding this topic or is 1997 the first date with historical records?? Tabulation of the data may clean up this section, but otherwise great find!&lt;br /&gt;
&lt;br /&gt;
Under the benefits section, no actual benefits seems to have been listed? I think this section has not yet been completed&lt;br /&gt;
&lt;br /&gt;
The pictures and information under the ‘Technical Progression’ subheading is substantial and informative. The images seem to have been referenced and labelled accordingly but not sure if they are reusable as the sites / locations you obtained them from do not mention permission rights for reuse of their material. Some of the referencing done still shows the blue PMID which disrupts the flow of the project page.&lt;br /&gt;
&lt;br /&gt;
It is clear that a lot of research has been done into making this page what it is currently. I would suggest firstly to check that all material used on your page is re-useable as well as fixing up the minor coding of references and also grammar and spelling mistakes throughout the page. Great work!!&lt;br /&gt;
&lt;br /&gt;
'''Group 3'''&lt;br /&gt;
&lt;br /&gt;
Straight away I was impressed by the images and the table of contents. It appears that all subheadings are relevant and well planned. Having the definition in the introduction was great as well as the addition of epidemiology including the map, however I think it would be much more informative for readers if you touched on the variety of topics your wikipage will be covering (if they did not bother to read the table of contents)&lt;br /&gt;
&lt;br /&gt;
The variety of causes which are mentioned for Female infertility was concise and very informative under their respective sub-subheadings and with the appropriate referencing. There is a substantial amount of information provided under the ‘Pathogenesis’ section which clearly defines the different types, however, it seems that rather than Female infertility you have focused more information on ‘PCOS’ rather than all round? The images added in this heading was great in breaking up the text and the addition of animal and cell culture models were a really nice addition&lt;br /&gt;
&lt;br /&gt;
The signs and symptoms section is nice and simple while giving the reader all the necessary information without lines and lines of text which makes the information easy to access however in a section of ‘Diagnosis’, I think use of paragraphing may help the reader take rests to understand the large amount of information provided in the blood testing, maybe make use of a glossary for the bolded words. Other than that the image has been reference properly and the subheadings were helpful&lt;br /&gt;
&lt;br /&gt;
The tabulated information in Prevention and Treatment was a great way to avoid walls and walls of text as some of the other groups have done clearly identifying the cons of certain ‘current’ treatment methods. The amount of references that went into making this wikipage is a clear indication of how much effort was put in to making this page what it is&lt;br /&gt;
&lt;br /&gt;
Great job on the project so far!! Only thing I can say is to try look for a video regarding Female infertility!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
I would like to say great work of find substantial information and images to go along with your wikipage. From the table of contents there seems to be a lot of topics being addressed and with your use of subheadings, it makes navigating the page much easier. The short introduction described the basic meaning of male infertility well as well as the inclusion of some basic statistics is a nice bit of information however it would be nice to have some information regarding what your wikipage will be covering in general&lt;br /&gt;
&lt;br /&gt;
The background information is very useless as it provides the reader with some basic knowledge of where the male reproductive system and its components come into play in regard to the topic of male infertility. The images used are all referenced appropriately and assists in understanding where each component is located and what they look like. The tabulated data of the different types of male infertility allows the readers to easily understand the different kinds and what their relative symptoms are easily. Good job on that! The use of video is nice to see, it has relevance to your topic.&lt;br /&gt;
&lt;br /&gt;
Regarding information within the section ‘Major Causes of Infertility’, the information provided is awesome, however there just seems to be too much information crammed into small paragraphs which makes it quite draining to read. There are many terms which some readers may not know or understand, so I recommend using a glossary to help sort this problem out  maybe simplify the information (if you can)  or break up into more paragraphs to make it easier to read and digest. There are some sections which have no information, however I know that these will be filled by the submission date. The large amount of references is indicative of how much work went into the wikipage for your group! &lt;br /&gt;
&lt;br /&gt;
Good work guys!!&lt;br /&gt;
&lt;br /&gt;
''' Group 5 '''&lt;br /&gt;
&lt;br /&gt;
Great work so far on your wikipage guys, even just at first glance it is clear how much research and work was put in to make this page what it is. The amount of information that has been provided on the page is quite substantial. Within the contents table at the top of the page, each section has been broken down accordingly allowing ease of navigation for those who wish to know more about Oncofertility. The introduction provides us with a nice description of what Oncofertility is as well as a definition of the term ‘infertility’ which is helpful to those who do not know much information regarding the terms&lt;br /&gt;
&lt;br /&gt;
I think that some information can be split up into more paragraphs, especially information in the subheading ‘Radiation’, currently it is just a wall of text which makes it extremely hard to focus and understand all the words. Seeing as it is a procedure, maybe someone can include a hand-drawn image of the process and how affects the body?&lt;br /&gt;
&lt;br /&gt;
Information in the other sections are well organised and provides useful relevant information as well as providing deeper knowledge into certain techniques, chemicals and cancer cells in general. The information is a good addition (for both cancer cells and chemotherapy  however there is no referencing available to be found for both your videos. I think more images (hand-drawn or from other resources) need to be added to balance out the amount of text you have on your page.&lt;br /&gt;
&lt;br /&gt;
The overall structure other than the main subheadings that you currently have could be improved as some sections are just too long and cover a too broad information to be just kept under one subheading. Make use of more dot points to summarise the information. The table under Fertility preservation in women was concise and provides easy to read data, however the colouring of the background makes it hard to distinguish where each section of the box finishes and ends (maybe I’m colour-blind). I also think that it might be helpful to add a glossary to the bottom of your wikipage as there are quite a lot of terms that people may not understand &lt;br /&gt;
&lt;br /&gt;
Overall great work on your wikipage, I look forward to reading the final version!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
Skimming through the page, it is clear that a lot of research has been done to make this page what it is, each subheading is well thought out (maybe a overdone a bit by the additional sub-subheadings) and allows a transition. However there is a crucial part of the page is missing, the introduction. By not having an introduction at the beginning of the page, the project just jumps straight into information giving no clues as to what the project will be covering overall. It would be nice to have a concise definition of Artificial Reproductive Technologies (maybe replace ‘ART’ for the full word for the wikipage heading) The history has some nice information, but I think it can be improved by making use of tables or a graph for each of the dates, or even dot points to break the constant text.&lt;br /&gt;
&lt;br /&gt;
Overall in the other sections, the pictures are nice and are references appropriately and the use of table is nice (might be a bit dark to see the writing clearly). I think that some of the information can be broken up into small paragraphs rather than having one paragraph with around 30~40 sentences as it breaks down the information into easily digestible parts considering the amount of information which has been provided. &lt;br /&gt;
&lt;br /&gt;
The advantages and disadvantages of ART have been mentioned clearly without using lots of text, it makes the information easy to understand. I also think that more images are needed considering the widespread nature of the topic you have chosen, maybe some hand drawn images for those which you cannot find copyright information or a video to explain some of the procedures. Some grammar and formatting should be done before final submission to ensure that all sections are uniform in their font and sizing.&lt;br /&gt;
&lt;br /&gt;
Great work on finding all the information and making this page so far!! Good luck&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment ==&lt;br /&gt;
&lt;br /&gt;
'''[https://embryology.med.unsw.edu.au/embryology/Slides/Embryo_Stages/Stage22/08-eye/Stage22-08-eye.html?zoom=5&amp;amp;lat=-2259.81863&amp;amp;lon=4843.06006&amp;amp;layers=B Cillary Body]'''&lt;br /&gt;
&lt;br /&gt;
The cillary body is the section of the eye which houses the cillary muscle, which works to control the shape of the lens, and also the cillary epithelium, which produces the aqueous humor. It is a circular thickening of the walls within the eyes which divides the vitreous body from the posterior chamber. The inner layer is transparent and continuous with the neural tissues of the retina whilst the outer layer is highly pigmented and runs continuous with the retinal pigment epithelium and forms the cells of the dilator muscle.&lt;br /&gt;
&lt;br /&gt;
'''Embryology Link''' [[Vision - Retina Development#Retinal Pigment Epithelium]]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26244658&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
Look at this aye &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26244657&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;References/&amp;gt;&lt;br /&gt;
[[Test student 2015]]&lt;br /&gt;
{{StudentPage2015}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209653</id>
		<title>User:Z3374116</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209653"/>
		<updated>2015-10-29T14:56:50Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 17:18, 5 August 2015 (AEST) Note your student number is already blue, as you have been previously enrolled in this course.&lt;br /&gt;
&lt;br /&gt;
Resource Investigator&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 13:45, 7 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:12, 14 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:08, 21 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:03, 4 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:16, 11 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:26, 18 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:44, 25 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:13, 9 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:35, 16 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 23 October 2015 - Attendance did not log properly (heart formation lab where you went though our projects and said it was too pink)&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 1==&lt;br /&gt;
&lt;br /&gt;
'''Article 1'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26260201&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This article was written in aims to evaluate a prospectively implemented clinical algorithm which served in the early identifications of Ectopic pregnancy (EP) and Heterotopic pregnancy (HP) after use of assisted reproductive technologies (In-vitro fertilization). The data used in this research were patients who all received in-vitro fertilization or other methods of Assisted reproductive technology from between January 1995 to June 2013. &lt;br /&gt;
&lt;br /&gt;
The early pregnancy stage was monitored using clinical algorithms where all pregnancies were screened using Human chorionic gonadotropin (hCG) levels and any reported symptoms during pregnancy as well as use of ultrasound evaluations where hCG levels were abnormal or patient reported any pains.&lt;br /&gt;
&lt;br /&gt;
The research found that within the 3904 pregnancies included in the data, the incidence of Ectopic and Heterotopic pregnancies were 0.77% and 0.46% respectively. The clinical algorithm managed to detect and select 96.7% of the 0.77% diagnosed with EP as well as 83.3% of the 0.46% diagnosed with HP leading to earlier treatment and resolution of the problem. These results showed the effectiveness of the developed clinical algorithm in the early identification and prompt intervention of EP and HP bypassing the catastrophic morbidity associated with delayed diagnosis&lt;br /&gt;
&lt;br /&gt;
'''Article 2'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;24939956&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
	The article researched the effects of different levels of progesterone on the day of human gonadotropin administration in the live birth delivery rates during in-vitro fertilization. Previous researches have shown that the presence of late follicular phase progesterone is essential for follicular development, ovulation and endometrial receptivity. Studies were carried out on 2723 cycles performed in patients aged between 19 ~35 years of age and undergoing controlled ovarian stimulation.&lt;br /&gt;
&lt;br /&gt;
	The patients underwent ovarian stimulation using a gonadotropin releasing hormone antagonist for pituitary down-regulation and then final oocyte maturation was triggered using hCG 36h before oocyte retrieval. On the day of hCG administration, progesterone evaluation was performed and live birth delivery rates were compared at regular progesterone intervals.&lt;br /&gt;
&lt;br /&gt;
	The study found that live birth rates were significantly lower in patients with bow low (&amp;lt;0.5 ng/ml) and high (&amp;gt;1.5 ng/ml) late follicular progesterone levels.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:09, 4 September 2015 (AEST) These are good summaries of the 2 papers with correct reference format. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 2 ==&lt;br /&gt;
&lt;br /&gt;
[[File:Biopsy of Morula Stage Embryo.png|700px]]&lt;br /&gt;
&lt;br /&gt;
'''Biopsy of a Morula Stage Embryo'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25191937&amp;lt;/pubmed&amp;gt;|[http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106433]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:10, 4 September 2015 (AEST) Image uploaded correctly with reference, copyright and student template. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 3 ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26246873&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:11, 4 September 2015 (AEST) These 3 references relate to your project topic. It would have been good to include even just a single sentence explaining why you selected these 3. (4/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 4 - Quiz ==&lt;br /&gt;
&lt;br /&gt;
=== Mesoderm Development ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Cells which migrate from '''somites''' form: &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Respiratory System&lt;br /&gt;
- Smooth Muscles&lt;br /&gt;
- Digestive System&lt;br /&gt;
+ Skeletal Muscles&lt;br /&gt;
- Reproductive System&lt;br /&gt;
|| '''Somites arise from the Paraxial Mesoderm and give rise to skeletal muscles as well as other musculoskeletal structures'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Fertilization ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Which of the following statements are '''INCORRECT''' regarding Implantation? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Implantation commences at day 6 ~ 7&lt;br /&gt;
+ The blastocyst rolls along the uterine wall to align the inner cell mass furthest from the uterine epithelium&lt;br /&gt;
- Implantation is the process in which a blastocyst enters the uterine wall&lt;br /&gt;
- A coagulation plug forms where the blastocyst has entered the uterine wall&lt;br /&gt;
|| '''The blastocyst initially rolls down the uterine walls aligning the inner cell mass to be closest to the uterine epithelium before implantation occurs. After the blastocyst has entered the Uterine wall, a coagulation plug forms at the site of implantation'''&lt;br /&gt;
&lt;br /&gt;
{At which of the following layers does Implantation occur? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Myometrium&lt;br /&gt;
- Spongy layer of Endometrium&lt;br /&gt;
- Perimetrium&lt;br /&gt;
+ Compact layer of Endometrium&lt;br /&gt;
- Implantation layer of Endometrium&lt;br /&gt;
|| '''Implantation occurs in the Compact layer of Endometrium containing  dense stromal cells, uterine gland necks and capillaries of spiral arteries'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:12, 4 September 2015 (AEST) 3 questions here please. I will assess after the lab today.&lt;br /&gt;
&lt;br /&gt;
[[ANAT2341 Student 2015 Quiz Questions]]&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 5 ==&lt;br /&gt;
&lt;br /&gt;
'''What is the difference between Gastroschisis and Omphalocele?'''&lt;br /&gt;
&lt;br /&gt;
Omphalocele is fetal defect (occurring 1 in every 4000 births) which is defined as the herniation of the abdominal viscera into the umbilical cord. In this abdominal wall defect, internal abdominal organs such as the intestines, liver protrude outside of the belly via the belly button where the organs are covered by a thin, opaque sac which separates the internal organs with the fluids in the amniotic sac during pregnancy. The occurrence of Omphalocele is due to the incorrect or incomplete development of the muscles of the abdominal wall. &lt;br /&gt;
&lt;br /&gt;
Gastroschisis is a defect which is thought to have been caused due to the interruption of blood supply to the developing abdominal wall from the omphalomesenteric duct artery in the 8th week of gestation. Unlike Omphalocele occurring from the belly button, it is characterized by an extra-umbilical herniation of internal abdominal organs at the junction of umbilicus and normal skin (beside the belly button) and not enclosed in visceral peritoneum. &lt;br /&gt;
&lt;br /&gt;
Omphalocele develops in the 9th week of development when the intestines do not re-enter the body cavity whereas Gastroschisis arises within the 6th ~ 7th week of development when the abdominal wall muscles of the baby do not develop properly&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''&amp;lt;pubmed&amp;gt;2932813&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;12130917&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;15305094&amp;lt;/pubmed&amp;gt;'''&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 7==&lt;br /&gt;
'''1. Identify and write a brief description of the findings of a recent research paper on development of one of the endocrine organs covered in today's practical.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''2. Identify the embryonic layers and tissues that contribute to the developing teeth.'''&lt;br /&gt;
&lt;br /&gt;
Tooth development (Odontogenesis) begins in the 6th week of embryonic development and is made up of ectoderm, mesoderm and neural crest ectomesenchyme&lt;br /&gt;
&lt;br /&gt;
-	'''Ameloblasts''': derived from the epithelium of ectoderm cells from the 1st pharyngeal arch which produces the enamel. Enamel covers the crown of the tooth and are only found to be present during the process of odontogenesis&lt;br /&gt;
&lt;br /&gt;
-	'''Odontoblasts''': ectomesenchymal cells derived from the neural crest. These cells begin by forming the predentin which later hardens to become dentin&lt;br /&gt;
&lt;br /&gt;
==Peer Reviews==&lt;br /&gt;
&lt;br /&gt;
'''Group 1'''&lt;br /&gt;
&lt;br /&gt;
From first glance of the page, just by looking at the contents table found at the top of the wikipage, I can already see that all the sections have been planned and well thought out with the appropriate subheadings and sub-subheadings which makes the page a lot easier to navigate if I were to be searching for something in particular on the topic ‘Three Person Embryo’&lt;br /&gt;
&lt;br /&gt;
The introduction is short and concise with the appropriate description of what the topic is about, adding the YouTube video in your introduction was a great touch (props to you for asking the maker permission to re-use as it’s under the YouTube Standard License) however I think this section could be improved by maybe addressing the key points that the wiki page will be covering&lt;br /&gt;
&lt;br /&gt;
It’s great to see some history behind the development and progression of ‘Mitochondrial’ Donation throughout the years!! Is there any more history regarding this topic or is 1997 the first date with historical records?? Tabulation of the data may clean up this section, but otherwise great find!&lt;br /&gt;
&lt;br /&gt;
Under the benefits section, no actual benefits seems to have been listed? I think this section has not yet been completed&lt;br /&gt;
&lt;br /&gt;
The pictures and information under the ‘Technical Progression’ subheading is substantial and informative. The images seem to have been referenced and labelled accordingly but not sure if they are reusable as the sites / locations you obtained them from do not mention permission rights for reuse of their material. Some of the referencing done still shows the blue PMID which disrupts the flow of the project page.&lt;br /&gt;
&lt;br /&gt;
It is clear that a lot of research has been done into making this page what it is currently. I would suggest firstly to check that all material used on your page is re-useable as well as fixing up the minor coding of references and also grammar and spelling mistakes throughout the page. Great work!!&lt;br /&gt;
&lt;br /&gt;
'''Group 3'''&lt;br /&gt;
&lt;br /&gt;
Straight away I was impressed by the images and the table of contents. It appears that all subheadings are relevant and well planned. Having the definition in the introduction was great as well as the addition of epidemiology including the map, however I think it would be much more informative for readers if you touched on the variety of topics your wikipage will be covering (if they did not bother to read the table of contents)&lt;br /&gt;
&lt;br /&gt;
The variety of causes which are mentioned for Female infertility was concise and very informative under their respective sub-subheadings and with the appropriate referencing. There is a substantial amount of information provided under the ‘Pathogenesis’ section which clearly defines the different types, however, it seems that rather than Female infertility you have focused more information on ‘PCOS’ rather than all round? The images added in this heading was great in breaking up the text and the addition of animal and cell culture models were a really nice addition&lt;br /&gt;
&lt;br /&gt;
The signs and symptoms section is nice and simple while giving the reader all the necessary information without lines and lines of text which makes the information easy to access however in a section of ‘Diagnosis’, I think use of paragraphing may help the reader take rests to understand the large amount of information provided in the blood testing, maybe make use of a glossary for the bolded words. Other than that the image has been reference properly and the subheadings were helpful&lt;br /&gt;
&lt;br /&gt;
The tabulated information in Prevention and Treatment was a great way to avoid walls and walls of text as some of the other groups have done clearly identifying the cons of certain ‘current’ treatment methods. The amount of references that went into making this wikipage is a clear indication of how much effort was put in to making this page what it is&lt;br /&gt;
&lt;br /&gt;
Great job on the project so far!! Only thing I can say is to try look for a video regarding Female infertility!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
I would like to say great work of find substantial information and images to go along with your wikipage. From the table of contents there seems to be a lot of topics being addressed and with your use of subheadings, it makes navigating the page much easier. The short introduction described the basic meaning of male infertility well as well as the inclusion of some basic statistics is a nice bit of information however it would be nice to have some information regarding what your wikipage will be covering in general&lt;br /&gt;
&lt;br /&gt;
The background information is very useless as it provides the reader with some basic knowledge of where the male reproductive system and its components come into play in regard to the topic of male infertility. The images used are all referenced appropriately and assists in understanding where each component is located and what they look like. The tabulated data of the different types of male infertility allows the readers to easily understand the different kinds and what their relative symptoms are easily. Good job on that! The use of video is nice to see, it has relevance to your topic.&lt;br /&gt;
&lt;br /&gt;
Regarding information within the section ‘Major Causes of Infertility’, the information provided is awesome, however there just seems to be too much information crammed into small paragraphs which makes it quite draining to read. There are many terms which some readers may not know or understand, so I recommend using a glossary to help sort this problem out  maybe simplify the information (if you can)  or break up into more paragraphs to make it easier to read and digest. There are some sections which have no information, however I know that these will be filled by the submission date. The large amount of references is indicative of how much work went into the wikipage for your group! &lt;br /&gt;
&lt;br /&gt;
Good work guys!!&lt;br /&gt;
&lt;br /&gt;
''' Group 5 '''&lt;br /&gt;
&lt;br /&gt;
Great work so far on your wikipage guys, even just at first glance it is clear how much research and work was put in to make this page what it is. The amount of information that has been provided on the page is quite substantial. Within the contents table at the top of the page, each section has been broken down accordingly allowing ease of navigation for those who wish to know more about Oncofertility. The introduction provides us with a nice description of what Oncofertility is as well as a definition of the term ‘infertility’ which is helpful to those who do not know much information regarding the terms&lt;br /&gt;
&lt;br /&gt;
I think that some information can be split up into more paragraphs, especially information in the subheading ‘Radiation’, currently it is just a wall of text which makes it extremely hard to focus and understand all the words. Seeing as it is a procedure, maybe someone can include a hand-drawn image of the process and how affects the body?&lt;br /&gt;
&lt;br /&gt;
Information in the other sections are well organised and provides useful relevant information as well as providing deeper knowledge into certain techniques, chemicals and cancer cells in general. The information is a good addition (for both cancer cells and chemotherapy  however there is no referencing available to be found for both your videos. I think more images (hand-drawn or from other resources) need to be added to balance out the amount of text you have on your page.&lt;br /&gt;
&lt;br /&gt;
The overall structure other than the main subheadings that you currently have could be improved as some sections are just too long and cover a too broad information to be just kept under one subheading. Make use of more dot points to summarise the information. The table under Fertility preservation in women was concise and provides easy to read data, however the colouring of the background makes it hard to distinguish where each section of the box finishes and ends (maybe I’m colour-blind). I also think that it might be helpful to add a glossary to the bottom of your wikipage as there are quite a lot of terms that people may not understand &lt;br /&gt;
&lt;br /&gt;
Overall great work on your wikipage, I look forward to reading the final version!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
Skimming through the page, it is clear that a lot of research has been done to make this page what it is, each subheading is well thought out (maybe a overdone a bit by the additional sub-subheadings) and allows a transition. However there is a crucial part of the page is missing, the introduction. By not having an introduction at the beginning of the page, the project just jumps straight into information giving no clues as to what the project will be covering overall. It would be nice to have a concise definition of Artificial Reproductive Technologies (maybe replace ‘ART’ for the full word for the wikipage heading) The history has some nice information, but I think it can be improved by making use of tables or a graph for each of the dates, or even dot points to break the constant text.&lt;br /&gt;
&lt;br /&gt;
Overall in the other sections, the pictures are nice and are references appropriately and the use of table is nice (might be a bit dark to see the writing clearly). I think that some of the information can be broken up into small paragraphs rather than having one paragraph with around 30~40 sentences as it breaks down the information into easily digestible parts considering the amount of information which has been provided. &lt;br /&gt;
&lt;br /&gt;
The advantages and disadvantages of ART have been mentioned clearly without using lots of text, it makes the information easy to understand. I also think that more images are needed considering the widespread nature of the topic you have chosen, maybe some hand drawn images for those which you cannot find copyright information or a video to explain some of the procedures. Some grammar and formatting should be done before final submission to ensure that all sections are uniform in their font and sizing.&lt;br /&gt;
&lt;br /&gt;
Great work on finding all the information and making this page so far!! Good luck&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment ==&lt;br /&gt;
&lt;br /&gt;
'''[https://embryology.med.unsw.edu.au/embryology/Slides/Embryo_Stages/Stage22/08-eye/Stage22-08-eye.html?zoom=5&amp;amp;lat=-2259.81863&amp;amp;lon=4843.06006&amp;amp;layers=B Cillary Body]'''&lt;br /&gt;
&lt;br /&gt;
The cillary body is the section of the eye which houses the cillary muscle, which works to control the shape of the lens, and also the cillary epithelium, which produces the aqueous humor. It is a circular thickening of the walls within the eyes which divides the vitreous body from the posterior chamber. The inner layer is transparent and continuous with the neural tissues of the retina whilst the outer layer is highly pigmented and runs continuous with the retinal pigment epithelium and forms the cells of the dilator muscle.&lt;br /&gt;
&lt;br /&gt;
'''Embryology Link''' [[Vision - Retina Development#Retinal Pigment Epithelium]]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26244658&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
Look at this aye &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26244657&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;References/&amp;gt;&lt;br /&gt;
[[Test student 2015]]&lt;br /&gt;
{{StudentPage2015}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209649</id>
		<title>User:Z3374116</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209649"/>
		<updated>2015-10-29T14:56:39Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 17:18, 5 August 2015 (AEST) Note your student number is already blue, as you have been previously enrolled in this course.&lt;br /&gt;
&lt;br /&gt;
Resource Investigator&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 13:45, 7 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:12, 14 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:08, 21 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:03, 4 September 2015 (AEST) - Left early for funeral&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:16, 11 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:26, 18 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:44, 25 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:13, 9 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:35, 16 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 23 October 2015 - Attendance did not log properly (heart formation lab where you went though our projects and said it was too pink)&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 1==&lt;br /&gt;
&lt;br /&gt;
'''Article 1'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26260201&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This article was written in aims to evaluate a prospectively implemented clinical algorithm which served in the early identifications of Ectopic pregnancy (EP) and Heterotopic pregnancy (HP) after use of assisted reproductive technologies (In-vitro fertilization). The data used in this research were patients who all received in-vitro fertilization or other methods of Assisted reproductive technology from between January 1995 to June 2013. &lt;br /&gt;
&lt;br /&gt;
The early pregnancy stage was monitored using clinical algorithms where all pregnancies were screened using Human chorionic gonadotropin (hCG) levels and any reported symptoms during pregnancy as well as use of ultrasound evaluations where hCG levels were abnormal or patient reported any pains.&lt;br /&gt;
&lt;br /&gt;
The research found that within the 3904 pregnancies included in the data, the incidence of Ectopic and Heterotopic pregnancies were 0.77% and 0.46% respectively. The clinical algorithm managed to detect and select 96.7% of the 0.77% diagnosed with EP as well as 83.3% of the 0.46% diagnosed with HP leading to earlier treatment and resolution of the problem. These results showed the effectiveness of the developed clinical algorithm in the early identification and prompt intervention of EP and HP bypassing the catastrophic morbidity associated with delayed diagnosis&lt;br /&gt;
&lt;br /&gt;
'''Article 2'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;24939956&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
	The article researched the effects of different levels of progesterone on the day of human gonadotropin administration in the live birth delivery rates during in-vitro fertilization. Previous researches have shown that the presence of late follicular phase progesterone is essential for follicular development, ovulation and endometrial receptivity. Studies were carried out on 2723 cycles performed in patients aged between 19 ~35 years of age and undergoing controlled ovarian stimulation.&lt;br /&gt;
&lt;br /&gt;
	The patients underwent ovarian stimulation using a gonadotropin releasing hormone antagonist for pituitary down-regulation and then final oocyte maturation was triggered using hCG 36h before oocyte retrieval. On the day of hCG administration, progesterone evaluation was performed and live birth delivery rates were compared at regular progesterone intervals.&lt;br /&gt;
&lt;br /&gt;
	The study found that live birth rates were significantly lower in patients with bow low (&amp;lt;0.5 ng/ml) and high (&amp;gt;1.5 ng/ml) late follicular progesterone levels.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:09, 4 September 2015 (AEST) These are good summaries of the 2 papers with correct reference format. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 2 ==&lt;br /&gt;
&lt;br /&gt;
[[File:Biopsy of Morula Stage Embryo.png|700px]]&lt;br /&gt;
&lt;br /&gt;
'''Biopsy of a Morula Stage Embryo'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25191937&amp;lt;/pubmed&amp;gt;|[http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106433]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:10, 4 September 2015 (AEST) Image uploaded correctly with reference, copyright and student template. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 3 ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26246873&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:11, 4 September 2015 (AEST) These 3 references relate to your project topic. It would have been good to include even just a single sentence explaining why you selected these 3. (4/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 4 - Quiz ==&lt;br /&gt;
&lt;br /&gt;
=== Mesoderm Development ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Cells which migrate from '''somites''' form: &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Respiratory System&lt;br /&gt;
- Smooth Muscles&lt;br /&gt;
- Digestive System&lt;br /&gt;
+ Skeletal Muscles&lt;br /&gt;
- Reproductive System&lt;br /&gt;
|| '''Somites arise from the Paraxial Mesoderm and give rise to skeletal muscles as well as other musculoskeletal structures'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Fertilization ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Which of the following statements are '''INCORRECT''' regarding Implantation? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Implantation commences at day 6 ~ 7&lt;br /&gt;
+ The blastocyst rolls along the uterine wall to align the inner cell mass furthest from the uterine epithelium&lt;br /&gt;
- Implantation is the process in which a blastocyst enters the uterine wall&lt;br /&gt;
- A coagulation plug forms where the blastocyst has entered the uterine wall&lt;br /&gt;
|| '''The blastocyst initially rolls down the uterine walls aligning the inner cell mass to be closest to the uterine epithelium before implantation occurs. After the blastocyst has entered the Uterine wall, a coagulation plug forms at the site of implantation'''&lt;br /&gt;
&lt;br /&gt;
{At which of the following layers does Implantation occur? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Myometrium&lt;br /&gt;
- Spongy layer of Endometrium&lt;br /&gt;
- Perimetrium&lt;br /&gt;
+ Compact layer of Endometrium&lt;br /&gt;
- Implantation layer of Endometrium&lt;br /&gt;
|| '''Implantation occurs in the Compact layer of Endometrium containing  dense stromal cells, uterine gland necks and capillaries of spiral arteries'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:12, 4 September 2015 (AEST) 3 questions here please. I will assess after the lab today.&lt;br /&gt;
&lt;br /&gt;
[[ANAT2341 Student 2015 Quiz Questions]]&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 5 ==&lt;br /&gt;
&lt;br /&gt;
'''What is the difference between Gastroschisis and Omphalocele?'''&lt;br /&gt;
&lt;br /&gt;
Omphalocele is fetal defect (occurring 1 in every 4000 births) which is defined as the herniation of the abdominal viscera into the umbilical cord. In this abdominal wall defect, internal abdominal organs such as the intestines, liver protrude outside of the belly via the belly button where the organs are covered by a thin, opaque sac which separates the internal organs with the fluids in the amniotic sac during pregnancy. The occurrence of Omphalocele is due to the incorrect or incomplete development of the muscles of the abdominal wall. &lt;br /&gt;
&lt;br /&gt;
Gastroschisis is a defect which is thought to have been caused due to the interruption of blood supply to the developing abdominal wall from the omphalomesenteric duct artery in the 8th week of gestation. Unlike Omphalocele occurring from the belly button, it is characterized by an extra-umbilical herniation of internal abdominal organs at the junction of umbilicus and normal skin (beside the belly button) and not enclosed in visceral peritoneum. &lt;br /&gt;
&lt;br /&gt;
Omphalocele develops in the 9th week of development when the intestines do not re-enter the body cavity whereas Gastroschisis arises within the 6th ~ 7th week of development when the abdominal wall muscles of the baby do not develop properly&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''&amp;lt;pubmed&amp;gt;2932813&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;12130917&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;15305094&amp;lt;/pubmed&amp;gt;'''&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 7==&lt;br /&gt;
'''1. Identify and write a brief description of the findings of a recent research paper on development of one of the endocrine organs covered in today's practical.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''2. Identify the embryonic layers and tissues that contribute to the developing teeth.'''&lt;br /&gt;
&lt;br /&gt;
Tooth development (Odontogenesis) begins in the 6th week of embryonic development and is made up of ectoderm, mesoderm and neural crest ectomesenchyme&lt;br /&gt;
&lt;br /&gt;
-	'''Ameloblasts''': derived from the epithelium of ectoderm cells from the 1st pharyngeal arch which produces the enamel. Enamel covers the crown of the tooth and are only found to be present during the process of odontogenesis&lt;br /&gt;
&lt;br /&gt;
-	'''Odontoblasts''': ectomesenchymal cells derived from the neural crest. These cells begin by forming the predentin which later hardens to become dentin&lt;br /&gt;
&lt;br /&gt;
==Peer Reviews==&lt;br /&gt;
&lt;br /&gt;
'''Group 1'''&lt;br /&gt;
&lt;br /&gt;
From first glance of the page, just by looking at the contents table found at the top of the wikipage, I can already see that all the sections have been planned and well thought out with the appropriate subheadings and sub-subheadings which makes the page a lot easier to navigate if I were to be searching for something in particular on the topic ‘Three Person Embryo’&lt;br /&gt;
&lt;br /&gt;
The introduction is short and concise with the appropriate description of what the topic is about, adding the YouTube video in your introduction was a great touch (props to you for asking the maker permission to re-use as it’s under the YouTube Standard License) however I think this section could be improved by maybe addressing the key points that the wiki page will be covering&lt;br /&gt;
&lt;br /&gt;
It’s great to see some history behind the development and progression of ‘Mitochondrial’ Donation throughout the years!! Is there any more history regarding this topic or is 1997 the first date with historical records?? Tabulation of the data may clean up this section, but otherwise great find!&lt;br /&gt;
&lt;br /&gt;
Under the benefits section, no actual benefits seems to have been listed? I think this section has not yet been completed&lt;br /&gt;
&lt;br /&gt;
The pictures and information under the ‘Technical Progression’ subheading is substantial and informative. The images seem to have been referenced and labelled accordingly but not sure if they are reusable as the sites / locations you obtained them from do not mention permission rights for reuse of their material. Some of the referencing done still shows the blue PMID which disrupts the flow of the project page.&lt;br /&gt;
&lt;br /&gt;
It is clear that a lot of research has been done into making this page what it is currently. I would suggest firstly to check that all material used on your page is re-useable as well as fixing up the minor coding of references and also grammar and spelling mistakes throughout the page. Great work!!&lt;br /&gt;
&lt;br /&gt;
'''Group 3'''&lt;br /&gt;
&lt;br /&gt;
Straight away I was impressed by the images and the table of contents. It appears that all subheadings are relevant and well planned. Having the definition in the introduction was great as well as the addition of epidemiology including the map, however I think it would be much more informative for readers if you touched on the variety of topics your wikipage will be covering (if they did not bother to read the table of contents)&lt;br /&gt;
&lt;br /&gt;
The variety of causes which are mentioned for Female infertility was concise and very informative under their respective sub-subheadings and with the appropriate referencing. There is a substantial amount of information provided under the ‘Pathogenesis’ section which clearly defines the different types, however, it seems that rather than Female infertility you have focused more information on ‘PCOS’ rather than all round? The images added in this heading was great in breaking up the text and the addition of animal and cell culture models were a really nice addition&lt;br /&gt;
&lt;br /&gt;
The signs and symptoms section is nice and simple while giving the reader all the necessary information without lines and lines of text which makes the information easy to access however in a section of ‘Diagnosis’, I think use of paragraphing may help the reader take rests to understand the large amount of information provided in the blood testing, maybe make use of a glossary for the bolded words. Other than that the image has been reference properly and the subheadings were helpful&lt;br /&gt;
&lt;br /&gt;
The tabulated information in Prevention and Treatment was a great way to avoid walls and walls of text as some of the other groups have done clearly identifying the cons of certain ‘current’ treatment methods. The amount of references that went into making this wikipage is a clear indication of how much effort was put in to making this page what it is&lt;br /&gt;
&lt;br /&gt;
Great job on the project so far!! Only thing I can say is to try look for a video regarding Female infertility!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
I would like to say great work of find substantial information and images to go along with your wikipage. From the table of contents there seems to be a lot of topics being addressed and with your use of subheadings, it makes navigating the page much easier. The short introduction described the basic meaning of male infertility well as well as the inclusion of some basic statistics is a nice bit of information however it would be nice to have some information regarding what your wikipage will be covering in general&lt;br /&gt;
&lt;br /&gt;
The background information is very useless as it provides the reader with some basic knowledge of where the male reproductive system and its components come into play in regard to the topic of male infertility. The images used are all referenced appropriately and assists in understanding where each component is located and what they look like. The tabulated data of the different types of male infertility allows the readers to easily understand the different kinds and what their relative symptoms are easily. Good job on that! The use of video is nice to see, it has relevance to your topic.&lt;br /&gt;
&lt;br /&gt;
Regarding information within the section ‘Major Causes of Infertility’, the information provided is awesome, however there just seems to be too much information crammed into small paragraphs which makes it quite draining to read. There are many terms which some readers may not know or understand, so I recommend using a glossary to help sort this problem out  maybe simplify the information (if you can)  or break up into more paragraphs to make it easier to read and digest. There are some sections which have no information, however I know that these will be filled by the submission date. The large amount of references is indicative of how much work went into the wikipage for your group! &lt;br /&gt;
&lt;br /&gt;
Good work guys!!&lt;br /&gt;
&lt;br /&gt;
''' Group 5 '''&lt;br /&gt;
&lt;br /&gt;
Great work so far on your wikipage guys, even just at first glance it is clear how much research and work was put in to make this page what it is. The amount of information that has been provided on the page is quite substantial. Within the contents table at the top of the page, each section has been broken down accordingly allowing ease of navigation for those who wish to know more about Oncofertility. The introduction provides us with a nice description of what Oncofertility is as well as a definition of the term ‘infertility’ which is helpful to those who do not know much information regarding the terms&lt;br /&gt;
&lt;br /&gt;
I think that some information can be split up into more paragraphs, especially information in the subheading ‘Radiation’, currently it is just a wall of text which makes it extremely hard to focus and understand all the words. Seeing as it is a procedure, maybe someone can include a hand-drawn image of the process and how affects the body?&lt;br /&gt;
&lt;br /&gt;
Information in the other sections are well organised and provides useful relevant information as well as providing deeper knowledge into certain techniques, chemicals and cancer cells in general. The information is a good addition (for both cancer cells and chemotherapy  however there is no referencing available to be found for both your videos. I think more images (hand-drawn or from other resources) need to be added to balance out the amount of text you have on your page.&lt;br /&gt;
&lt;br /&gt;
The overall structure other than the main subheadings that you currently have could be improved as some sections are just too long and cover a too broad information to be just kept under one subheading. Make use of more dot points to summarise the information. The table under Fertility preservation in women was concise and provides easy to read data, however the colouring of the background makes it hard to distinguish where each section of the box finishes and ends (maybe I’m colour-blind). I also think that it might be helpful to add a glossary to the bottom of your wikipage as there are quite a lot of terms that people may not understand &lt;br /&gt;
&lt;br /&gt;
Overall great work on your wikipage, I look forward to reading the final version!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
Skimming through the page, it is clear that a lot of research has been done to make this page what it is, each subheading is well thought out (maybe a overdone a bit by the additional sub-subheadings) and allows a transition. However there is a crucial part of the page is missing, the introduction. By not having an introduction at the beginning of the page, the project just jumps straight into information giving no clues as to what the project will be covering overall. It would be nice to have a concise definition of Artificial Reproductive Technologies (maybe replace ‘ART’ for the full word for the wikipage heading) The history has some nice information, but I think it can be improved by making use of tables or a graph for each of the dates, or even dot points to break the constant text.&lt;br /&gt;
&lt;br /&gt;
Overall in the other sections, the pictures are nice and are references appropriately and the use of table is nice (might be a bit dark to see the writing clearly). I think that some of the information can be broken up into small paragraphs rather than having one paragraph with around 30~40 sentences as it breaks down the information into easily digestible parts considering the amount of information which has been provided. &lt;br /&gt;
&lt;br /&gt;
The advantages and disadvantages of ART have been mentioned clearly without using lots of text, it makes the information easy to understand. I also think that more images are needed considering the widespread nature of the topic you have chosen, maybe some hand drawn images for those which you cannot find copyright information or a video to explain some of the procedures. Some grammar and formatting should be done before final submission to ensure that all sections are uniform in their font and sizing.&lt;br /&gt;
&lt;br /&gt;
Great work on finding all the information and making this page so far!! Good luck&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment ==&lt;br /&gt;
&lt;br /&gt;
'''[https://embryology.med.unsw.edu.au/embryology/Slides/Embryo_Stages/Stage22/08-eye/Stage22-08-eye.html?zoom=5&amp;amp;lat=-2259.81863&amp;amp;lon=4843.06006&amp;amp;layers=B Cillary Body]'''&lt;br /&gt;
&lt;br /&gt;
The cillary body is the section of the eye which houses the cillary muscle, which works to control the shape of the lens, and also the cillary epithelium, which produces the aqueous humor. It is a circular thickening of the walls within the eyes which divides the vitreous body from the posterior chamber. The inner layer is transparent and continuous with the neural tissues of the retina whilst the outer layer is highly pigmented and runs continuous with the retinal pigment epithelium and forms the cells of the dilator muscle.&lt;br /&gt;
&lt;br /&gt;
'''Embryology Link''' [[Vision - Retina Development#Retinal Pigment Epithelium]]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26244658&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
Look at this aye &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26244657&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;References/&amp;gt;&lt;br /&gt;
[[Test student 2015]]&lt;br /&gt;
{{StudentPage2015}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209647</id>
		<title>User:Z3374116</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209647"/>
		<updated>2015-10-29T14:56:11Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 17:18, 5 August 2015 (AEST) Note your student number is already blue, as you have been previously enrolled in this course.&lt;br /&gt;
&lt;br /&gt;
Resource Investigator&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 13:45, 7 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:12, 14 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:08, 21 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:03, 4 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:16, 11 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:26, 18 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:44, 25 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:13, 9 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:35, 16 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 23 October 2015 - Attendance did not log properly (heart formation lab where you went though our projects and said it was too pink)&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 1==&lt;br /&gt;
&lt;br /&gt;
'''Article 1'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26260201&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This article was written in aims to evaluate a prospectively implemented clinical algorithm which served in the early identifications of Ectopic pregnancy (EP) and Heterotopic pregnancy (HP) after use of assisted reproductive technologies (In-vitro fertilization). The data used in this research were patients who all received in-vitro fertilization or other methods of Assisted reproductive technology from between January 1995 to June 2013. &lt;br /&gt;
&lt;br /&gt;
The early pregnancy stage was monitored using clinical algorithms where all pregnancies were screened using Human chorionic gonadotropin (hCG) levels and any reported symptoms during pregnancy as well as use of ultrasound evaluations where hCG levels were abnormal or patient reported any pains.&lt;br /&gt;
&lt;br /&gt;
The research found that within the 3904 pregnancies included in the data, the incidence of Ectopic and Heterotopic pregnancies were 0.77% and 0.46% respectively. The clinical algorithm managed to detect and select 96.7% of the 0.77% diagnosed with EP as well as 83.3% of the 0.46% diagnosed with HP leading to earlier treatment and resolution of the problem. These results showed the effectiveness of the developed clinical algorithm in the early identification and prompt intervention of EP and HP bypassing the catastrophic morbidity associated with delayed diagnosis&lt;br /&gt;
&lt;br /&gt;
'''Article 2'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;24939956&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
	The article researched the effects of different levels of progesterone on the day of human gonadotropin administration in the live birth delivery rates during in-vitro fertilization. Previous researches have shown that the presence of late follicular phase progesterone is essential for follicular development, ovulation and endometrial receptivity. Studies were carried out on 2723 cycles performed in patients aged between 19 ~35 years of age and undergoing controlled ovarian stimulation.&lt;br /&gt;
&lt;br /&gt;
	The patients underwent ovarian stimulation using a gonadotropin releasing hormone antagonist for pituitary down-regulation and then final oocyte maturation was triggered using hCG 36h before oocyte retrieval. On the day of hCG administration, progesterone evaluation was performed and live birth delivery rates were compared at regular progesterone intervals.&lt;br /&gt;
&lt;br /&gt;
	The study found that live birth rates were significantly lower in patients with bow low (&amp;lt;0.5 ng/ml) and high (&amp;gt;1.5 ng/ml) late follicular progesterone levels.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:09, 4 September 2015 (AEST) These are good summaries of the 2 papers with correct reference format. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 2 ==&lt;br /&gt;
&lt;br /&gt;
[[File:Biopsy of Morula Stage Embryo.png|700px]]&lt;br /&gt;
&lt;br /&gt;
'''Biopsy of a Morula Stage Embryo'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25191937&amp;lt;/pubmed&amp;gt;|[http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106433]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:10, 4 September 2015 (AEST) Image uploaded correctly with reference, copyright and student template. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 3 ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26246873&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:11, 4 September 2015 (AEST) These 3 references relate to your project topic. It would have been good to include even just a single sentence explaining why you selected these 3. (4/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 4 - Quiz ==&lt;br /&gt;
&lt;br /&gt;
=== Mesoderm Development ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Cells which migrate from '''somites''' form: &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Respiratory System&lt;br /&gt;
- Smooth Muscles&lt;br /&gt;
- Digestive System&lt;br /&gt;
+ Skeletal Muscles&lt;br /&gt;
- Reproductive System&lt;br /&gt;
|| '''Somites arise from the Paraxial Mesoderm and give rise to skeletal muscles as well as other musculoskeletal structures'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Fertilization ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Which of the following statements are '''INCORRECT''' regarding Implantation? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Implantation commences at day 6 ~ 7&lt;br /&gt;
+ The blastocyst rolls along the uterine wall to align the inner cell mass furthest from the uterine epithelium&lt;br /&gt;
- Implantation is the process in which a blastocyst enters the uterine wall&lt;br /&gt;
- A coagulation plug forms where the blastocyst has entered the uterine wall&lt;br /&gt;
|| '''The blastocyst initially rolls down the uterine walls aligning the inner cell mass to be closest to the uterine epithelium before implantation occurs. After the blastocyst has entered the Uterine wall, a coagulation plug forms at the site of implantation'''&lt;br /&gt;
&lt;br /&gt;
{At which of the following layers does Implantation occur? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Myometrium&lt;br /&gt;
- Spongy layer of Endometrium&lt;br /&gt;
- Perimetrium&lt;br /&gt;
+ Compact layer of Endometrium&lt;br /&gt;
- Implantation layer of Endometrium&lt;br /&gt;
|| '''Implantation occurs in the Compact layer of Endometrium containing  dense stromal cells, uterine gland necks and capillaries of spiral arteries'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:12, 4 September 2015 (AEST) 3 questions here please. I will assess after the lab today.&lt;br /&gt;
&lt;br /&gt;
[[ANAT2341 Student 2015 Quiz Questions]]&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 5 ==&lt;br /&gt;
&lt;br /&gt;
'''What is the difference between Gastroschisis and Omphalocele?'''&lt;br /&gt;
&lt;br /&gt;
Omphalocele is fetal defect (occurring 1 in every 4000 births) which is defined as the herniation of the abdominal viscera into the umbilical cord. In this abdominal wall defect, internal abdominal organs such as the intestines, liver protrude outside of the belly via the belly button where the organs are covered by a thin, opaque sac which separates the internal organs with the fluids in the amniotic sac during pregnancy. The occurrence of Omphalocele is due to the incorrect or incomplete development of the muscles of the abdominal wall. &lt;br /&gt;
&lt;br /&gt;
Gastroschisis is a defect which is thought to have been caused due to the interruption of blood supply to the developing abdominal wall from the omphalomesenteric duct artery in the 8th week of gestation. Unlike Omphalocele occurring from the belly button, it is characterized by an extra-umbilical herniation of internal abdominal organs at the junction of umbilicus and normal skin (beside the belly button) and not enclosed in visceral peritoneum. &lt;br /&gt;
&lt;br /&gt;
Omphalocele develops in the 9th week of development when the intestines do not re-enter the body cavity whereas Gastroschisis arises within the 6th ~ 7th week of development when the abdominal wall muscles of the baby do not develop properly&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''&amp;lt;pubmed&amp;gt;2932813&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;12130917&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;15305094&amp;lt;/pubmed&amp;gt;'''&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 7==&lt;br /&gt;
'''1. Identify and write a brief description of the findings of a recent research paper on development of one of the endocrine organs covered in today's practical.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''2. Identify the embryonic layers and tissues that contribute to the developing teeth.'''&lt;br /&gt;
&lt;br /&gt;
Tooth development (Odontogenesis) begins in the 6th week of embryonic development and is made up of ectoderm, mesoderm and neural crest ectomesenchyme&lt;br /&gt;
&lt;br /&gt;
-	'''Ameloblasts''': derived from the epithelium of ectoderm cells from the 1st pharyngeal arch which produces the enamel. Enamel covers the crown of the tooth and are only found to be present during the process of odontogenesis&lt;br /&gt;
&lt;br /&gt;
-	'''Odontoblasts''': ectomesenchymal cells derived from the neural crest. These cells begin by forming the predentin which later hardens to become dentin&lt;br /&gt;
&lt;br /&gt;
==Peer Reviews==&lt;br /&gt;
&lt;br /&gt;
'''Group 1'''&lt;br /&gt;
&lt;br /&gt;
From first glance of the page, just by looking at the contents table found at the top of the wikipage, I can already see that all the sections have been planned and well thought out with the appropriate subheadings and sub-subheadings which makes the page a lot easier to navigate if I were to be searching for something in particular on the topic ‘Three Person Embryo’&lt;br /&gt;
&lt;br /&gt;
The introduction is short and concise with the appropriate description of what the topic is about, adding the YouTube video in your introduction was a great touch (props to you for asking the maker permission to re-use as it’s under the YouTube Standard License) however I think this section could be improved by maybe addressing the key points that the wiki page will be covering&lt;br /&gt;
&lt;br /&gt;
It’s great to see some history behind the development and progression of ‘Mitochondrial’ Donation throughout the years!! Is there any more history regarding this topic or is 1997 the first date with historical records?? Tabulation of the data may clean up this section, but otherwise great find!&lt;br /&gt;
&lt;br /&gt;
Under the benefits section, no actual benefits seems to have been listed? I think this section has not yet been completed&lt;br /&gt;
&lt;br /&gt;
The pictures and information under the ‘Technical Progression’ subheading is substantial and informative. The images seem to have been referenced and labelled accordingly but not sure if they are reusable as the sites / locations you obtained them from do not mention permission rights for reuse of their material. Some of the referencing done still shows the blue PMID which disrupts the flow of the project page.&lt;br /&gt;
&lt;br /&gt;
It is clear that a lot of research has been done into making this page what it is currently. I would suggest firstly to check that all material used on your page is re-useable as well as fixing up the minor coding of references and also grammar and spelling mistakes throughout the page. Great work!!&lt;br /&gt;
&lt;br /&gt;
'''Group 3'''&lt;br /&gt;
&lt;br /&gt;
Straight away I was impressed by the images and the table of contents. It appears that all subheadings are relevant and well planned. Having the definition in the introduction was great as well as the addition of epidemiology including the map, however I think it would be much more informative for readers if you touched on the variety of topics your wikipage will be covering (if they did not bother to read the table of contents)&lt;br /&gt;
&lt;br /&gt;
The variety of causes which are mentioned for Female infertility was concise and very informative under their respective sub-subheadings and with the appropriate referencing. There is a substantial amount of information provided under the ‘Pathogenesis’ section which clearly defines the different types, however, it seems that rather than Female infertility you have focused more information on ‘PCOS’ rather than all round? The images added in this heading was great in breaking up the text and the addition of animal and cell culture models were a really nice addition&lt;br /&gt;
&lt;br /&gt;
The signs and symptoms section is nice and simple while giving the reader all the necessary information without lines and lines of text which makes the information easy to access however in a section of ‘Diagnosis’, I think use of paragraphing may help the reader take rests to understand the large amount of information provided in the blood testing, maybe make use of a glossary for the bolded words. Other than that the image has been reference properly and the subheadings were helpful&lt;br /&gt;
&lt;br /&gt;
The tabulated information in Prevention and Treatment was a great way to avoid walls and walls of text as some of the other groups have done clearly identifying the cons of certain ‘current’ treatment methods. The amount of references that went into making this wikipage is a clear indication of how much effort was put in to making this page what it is&lt;br /&gt;
&lt;br /&gt;
Great job on the project so far!! Only thing I can say is to try look for a video regarding Female infertility!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
I would like to say great work of find substantial information and images to go along with your wikipage. From the table of contents there seems to be a lot of topics being addressed and with your use of subheadings, it makes navigating the page much easier. The short introduction described the basic meaning of male infertility well as well as the inclusion of some basic statistics is a nice bit of information however it would be nice to have some information regarding what your wikipage will be covering in general&lt;br /&gt;
&lt;br /&gt;
The background information is very useless as it provides the reader with some basic knowledge of where the male reproductive system and its components come into play in regard to the topic of male infertility. The images used are all referenced appropriately and assists in understanding where each component is located and what they look like. The tabulated data of the different types of male infertility allows the readers to easily understand the different kinds and what their relative symptoms are easily. Good job on that! The use of video is nice to see, it has relevance to your topic.&lt;br /&gt;
&lt;br /&gt;
Regarding information within the section ‘Major Causes of Infertility’, the information provided is awesome, however there just seems to be too much information crammed into small paragraphs which makes it quite draining to read. There are many terms which some readers may not know or understand, so I recommend using a glossary to help sort this problem out  maybe simplify the information (if you can)  or break up into more paragraphs to make it easier to read and digest. There are some sections which have no information, however I know that these will be filled by the submission date. The large amount of references is indicative of how much work went into the wikipage for your group! &lt;br /&gt;
&lt;br /&gt;
Good work guys!!&lt;br /&gt;
&lt;br /&gt;
''' Group 5 '''&lt;br /&gt;
&lt;br /&gt;
Great work so far on your wikipage guys, even just at first glance it is clear how much research and work was put in to make this page what it is. The amount of information that has been provided on the page is quite substantial. Within the contents table at the top of the page, each section has been broken down accordingly allowing ease of navigation for those who wish to know more about Oncofertility. The introduction provides us with a nice description of what Oncofertility is as well as a definition of the term ‘infertility’ which is helpful to those who do not know much information regarding the terms&lt;br /&gt;
&lt;br /&gt;
I think that some information can be split up into more paragraphs, especially information in the subheading ‘Radiation’, currently it is just a wall of text which makes it extremely hard to focus and understand all the words. Seeing as it is a procedure, maybe someone can include a hand-drawn image of the process and how affects the body?&lt;br /&gt;
&lt;br /&gt;
Information in the other sections are well organised and provides useful relevant information as well as providing deeper knowledge into certain techniques, chemicals and cancer cells in general. The information is a good addition (for both cancer cells and chemotherapy  however there is no referencing available to be found for both your videos. I think more images (hand-drawn or from other resources) need to be added to balance out the amount of text you have on your page.&lt;br /&gt;
&lt;br /&gt;
The overall structure other than the main subheadings that you currently have could be improved as some sections are just too long and cover a too broad information to be just kept under one subheading. Make use of more dot points to summarise the information. The table under Fertility preservation in women was concise and provides easy to read data, however the colouring of the background makes it hard to distinguish where each section of the box finishes and ends (maybe I’m colour-blind). I also think that it might be helpful to add a glossary to the bottom of your wikipage as there are quite a lot of terms that people may not understand &lt;br /&gt;
&lt;br /&gt;
Overall great work on your wikipage, I look forward to reading the final version!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
Skimming through the page, it is clear that a lot of research has been done to make this page what it is, each subheading is well thought out (maybe a overdone a bit by the additional sub-subheadings) and allows a transition. However there is a crucial part of the page is missing, the introduction. By not having an introduction at the beginning of the page, the project just jumps straight into information giving no clues as to what the project will be covering overall. It would be nice to have a concise definition of Artificial Reproductive Technologies (maybe replace ‘ART’ for the full word for the wikipage heading) The history has some nice information, but I think it can be improved by making use of tables or a graph for each of the dates, or even dot points to break the constant text.&lt;br /&gt;
&lt;br /&gt;
Overall in the other sections, the pictures are nice and are references appropriately and the use of table is nice (might be a bit dark to see the writing clearly). I think that some of the information can be broken up into small paragraphs rather than having one paragraph with around 30~40 sentences as it breaks down the information into easily digestible parts considering the amount of information which has been provided. &lt;br /&gt;
&lt;br /&gt;
The advantages and disadvantages of ART have been mentioned clearly without using lots of text, it makes the information easy to understand. I also think that more images are needed considering the widespread nature of the topic you have chosen, maybe some hand drawn images for those which you cannot find copyright information or a video to explain some of the procedures. Some grammar and formatting should be done before final submission to ensure that all sections are uniform in their font and sizing.&lt;br /&gt;
&lt;br /&gt;
Great work on finding all the information and making this page so far!! Good luck&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment ==&lt;br /&gt;
&lt;br /&gt;
'''[https://embryology.med.unsw.edu.au/embryology/Slides/Embryo_Stages/Stage22/08-eye/Stage22-08-eye.html?zoom=5&amp;amp;lat=-2259.81863&amp;amp;lon=4843.06006&amp;amp;layers=B Cillary Body]'''&lt;br /&gt;
&lt;br /&gt;
The cillary body is the section of the eye which houses the cillary muscle, which works to control the shape of the lens, and also the cillary epithelium, which produces the aqueous humor. It is a circular thickening of the walls within the eyes which divides the vitreous body from the posterior chamber. The inner layer is transparent and continuous with the neural tissues of the retina whilst the outer layer is highly pigmented and runs continuous with the retinal pigment epithelium and forms the cells of the dilator muscle.&lt;br /&gt;
&lt;br /&gt;
'''Embryology Link''' [[Vision - Retina Development#Retinal Pigment Epithelium]]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26244658&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
Look at this aye &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26244657&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;References/&amp;gt;&lt;br /&gt;
[[Test student 2015]]&lt;br /&gt;
{{StudentPage2015}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209645</id>
		<title>User:Z3374116</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209645"/>
		<updated>2015-10-29T14:54:08Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 17:18, 5 August 2015 (AEST) Note your student number is already blue, as you have been previously enrolled in this course.&lt;br /&gt;
&lt;br /&gt;
Resource Investigator&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 13:45, 7 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:12, 14 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:08, 21 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:16, 11 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:26, 18 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:44, 25 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:13, 9 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:35, 16 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 23 October 2015 - Attendance did not log properly (heart formation lab where you went though our projects and said it was too pink)&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 1==&lt;br /&gt;
&lt;br /&gt;
'''Article 1'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26260201&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This article was written in aims to evaluate a prospectively implemented clinical algorithm which served in the early identifications of Ectopic pregnancy (EP) and Heterotopic pregnancy (HP) after use of assisted reproductive technologies (In-vitro fertilization). The data used in this research were patients who all received in-vitro fertilization or other methods of Assisted reproductive technology from between January 1995 to June 2013. &lt;br /&gt;
&lt;br /&gt;
The early pregnancy stage was monitored using clinical algorithms where all pregnancies were screened using Human chorionic gonadotropin (hCG) levels and any reported symptoms during pregnancy as well as use of ultrasound evaluations where hCG levels were abnormal or patient reported any pains.&lt;br /&gt;
&lt;br /&gt;
The research found that within the 3904 pregnancies included in the data, the incidence of Ectopic and Heterotopic pregnancies were 0.77% and 0.46% respectively. The clinical algorithm managed to detect and select 96.7% of the 0.77% diagnosed with EP as well as 83.3% of the 0.46% diagnosed with HP leading to earlier treatment and resolution of the problem. These results showed the effectiveness of the developed clinical algorithm in the early identification and prompt intervention of EP and HP bypassing the catastrophic morbidity associated with delayed diagnosis&lt;br /&gt;
&lt;br /&gt;
'''Article 2'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;24939956&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
	The article researched the effects of different levels of progesterone on the day of human gonadotropin administration in the live birth delivery rates during in-vitro fertilization. Previous researches have shown that the presence of late follicular phase progesterone is essential for follicular development, ovulation and endometrial receptivity. Studies were carried out on 2723 cycles performed in patients aged between 19 ~35 years of age and undergoing controlled ovarian stimulation.&lt;br /&gt;
&lt;br /&gt;
	The patients underwent ovarian stimulation using a gonadotropin releasing hormone antagonist for pituitary down-regulation and then final oocyte maturation was triggered using hCG 36h before oocyte retrieval. On the day of hCG administration, progesterone evaluation was performed and live birth delivery rates were compared at regular progesterone intervals.&lt;br /&gt;
&lt;br /&gt;
	The study found that live birth rates were significantly lower in patients with bow low (&amp;lt;0.5 ng/ml) and high (&amp;gt;1.5 ng/ml) late follicular progesterone levels.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:09, 4 September 2015 (AEST) These are good summaries of the 2 papers with correct reference format. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 2 ==&lt;br /&gt;
&lt;br /&gt;
[[File:Biopsy of Morula Stage Embryo.png|700px]]&lt;br /&gt;
&lt;br /&gt;
'''Biopsy of a Morula Stage Embryo'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25191937&amp;lt;/pubmed&amp;gt;|[http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106433]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:10, 4 September 2015 (AEST) Image uploaded correctly with reference, copyright and student template. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 3 ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26246873&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:11, 4 September 2015 (AEST) These 3 references relate to your project topic. It would have been good to include even just a single sentence explaining why you selected these 3. (4/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 4 - Quiz ==&lt;br /&gt;
&lt;br /&gt;
=== Mesoderm Development ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Cells which migrate from '''somites''' form: &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Respiratory System&lt;br /&gt;
- Smooth Muscles&lt;br /&gt;
- Digestive System&lt;br /&gt;
+ Skeletal Muscles&lt;br /&gt;
- Reproductive System&lt;br /&gt;
|| '''Somites arise from the Paraxial Mesoderm and give rise to skeletal muscles as well as other musculoskeletal structures'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Fertilization ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Which of the following statements are '''INCORRECT''' regarding Implantation? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Implantation commences at day 6 ~ 7&lt;br /&gt;
+ The blastocyst rolls along the uterine wall to align the inner cell mass furthest from the uterine epithelium&lt;br /&gt;
- Implantation is the process in which a blastocyst enters the uterine wall&lt;br /&gt;
- A coagulation plug forms where the blastocyst has entered the uterine wall&lt;br /&gt;
|| '''The blastocyst initially rolls down the uterine walls aligning the inner cell mass to be closest to the uterine epithelium before implantation occurs. After the blastocyst has entered the Uterine wall, a coagulation plug forms at the site of implantation'''&lt;br /&gt;
&lt;br /&gt;
{At which of the following layers does Implantation occur? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Myometrium&lt;br /&gt;
- Spongy layer of Endometrium&lt;br /&gt;
- Perimetrium&lt;br /&gt;
+ Compact layer of Endometrium&lt;br /&gt;
- Implantation layer of Endometrium&lt;br /&gt;
|| '''Implantation occurs in the Compact layer of Endometrium containing  dense stromal cells, uterine gland necks and capillaries of spiral arteries'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:12, 4 September 2015 (AEST) 3 questions here please. I will assess after the lab today.&lt;br /&gt;
&lt;br /&gt;
[[ANAT2341 Student 2015 Quiz Questions]]&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 5 ==&lt;br /&gt;
&lt;br /&gt;
'''What is the difference between Gastroschisis and Omphalocele?'''&lt;br /&gt;
&lt;br /&gt;
Omphalocele is fetal defect (occurring 1 in every 4000 births) which is defined as the herniation of the abdominal viscera into the umbilical cord. In this abdominal wall defect, internal abdominal organs such as the intestines, liver protrude outside of the belly via the belly button where the organs are covered by a thin, opaque sac which separates the internal organs with the fluids in the amniotic sac during pregnancy. The occurrence of Omphalocele is due to the incorrect or incomplete development of the muscles of the abdominal wall. &lt;br /&gt;
&lt;br /&gt;
Gastroschisis is a defect which is thought to have been caused due to the interruption of blood supply to the developing abdominal wall from the omphalomesenteric duct artery in the 8th week of gestation. Unlike Omphalocele occurring from the belly button, it is characterized by an extra-umbilical herniation of internal abdominal organs at the junction of umbilicus and normal skin (beside the belly button) and not enclosed in visceral peritoneum. &lt;br /&gt;
&lt;br /&gt;
Omphalocele develops in the 9th week of development when the intestines do not re-enter the body cavity whereas Gastroschisis arises within the 6th ~ 7th week of development when the abdominal wall muscles of the baby do not develop properly&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''&amp;lt;pubmed&amp;gt;2932813&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;12130917&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;15305094&amp;lt;/pubmed&amp;gt;'''&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 7==&lt;br /&gt;
'''1. Identify and write a brief description of the findings of a recent research paper on development of one of the endocrine organs covered in today's practical.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''2. Identify the embryonic layers and tissues that contribute to the developing teeth.'''&lt;br /&gt;
&lt;br /&gt;
Tooth development (Odontogenesis) begins in the 6th week of embryonic development and is made up of ectoderm, mesoderm and neural crest ectomesenchyme&lt;br /&gt;
&lt;br /&gt;
-	'''Ameloblasts''': derived from the epithelium of ectoderm cells from the 1st pharyngeal arch which produces the enamel. Enamel covers the crown of the tooth and are only found to be present during the process of odontogenesis&lt;br /&gt;
&lt;br /&gt;
-	'''Odontoblasts''': ectomesenchymal cells derived from the neural crest. These cells begin by forming the predentin which later hardens to become dentin&lt;br /&gt;
&lt;br /&gt;
==Peer Reviews==&lt;br /&gt;
&lt;br /&gt;
'''Group 1'''&lt;br /&gt;
&lt;br /&gt;
From first glance of the page, just by looking at the contents table found at the top of the wikipage, I can already see that all the sections have been planned and well thought out with the appropriate subheadings and sub-subheadings which makes the page a lot easier to navigate if I were to be searching for something in particular on the topic ‘Three Person Embryo’&lt;br /&gt;
&lt;br /&gt;
The introduction is short and concise with the appropriate description of what the topic is about, adding the YouTube video in your introduction was a great touch (props to you for asking the maker permission to re-use as it’s under the YouTube Standard License) however I think this section could be improved by maybe addressing the key points that the wiki page will be covering&lt;br /&gt;
&lt;br /&gt;
It’s great to see some history behind the development and progression of ‘Mitochondrial’ Donation throughout the years!! Is there any more history regarding this topic or is 1997 the first date with historical records?? Tabulation of the data may clean up this section, but otherwise great find!&lt;br /&gt;
&lt;br /&gt;
Under the benefits section, no actual benefits seems to have been listed? I think this section has not yet been completed&lt;br /&gt;
&lt;br /&gt;
The pictures and information under the ‘Technical Progression’ subheading is substantial and informative. The images seem to have been referenced and labelled accordingly but not sure if they are reusable as the sites / locations you obtained them from do not mention permission rights for reuse of their material. Some of the referencing done still shows the blue PMID which disrupts the flow of the project page.&lt;br /&gt;
&lt;br /&gt;
It is clear that a lot of research has been done into making this page what it is currently. I would suggest firstly to check that all material used on your page is re-useable as well as fixing up the minor coding of references and also grammar and spelling mistakes throughout the page. Great work!!&lt;br /&gt;
&lt;br /&gt;
'''Group 3'''&lt;br /&gt;
&lt;br /&gt;
Straight away I was impressed by the images and the table of contents. It appears that all subheadings are relevant and well planned. Having the definition in the introduction was great as well as the addition of epidemiology including the map, however I think it would be much more informative for readers if you touched on the variety of topics your wikipage will be covering (if they did not bother to read the table of contents)&lt;br /&gt;
&lt;br /&gt;
The variety of causes which are mentioned for Female infertility was concise and very informative under their respective sub-subheadings and with the appropriate referencing. There is a substantial amount of information provided under the ‘Pathogenesis’ section which clearly defines the different types, however, it seems that rather than Female infertility you have focused more information on ‘PCOS’ rather than all round? The images added in this heading was great in breaking up the text and the addition of animal and cell culture models were a really nice addition&lt;br /&gt;
&lt;br /&gt;
The signs and symptoms section is nice and simple while giving the reader all the necessary information without lines and lines of text which makes the information easy to access however in a section of ‘Diagnosis’, I think use of paragraphing may help the reader take rests to understand the large amount of information provided in the blood testing, maybe make use of a glossary for the bolded words. Other than that the image has been reference properly and the subheadings were helpful&lt;br /&gt;
&lt;br /&gt;
The tabulated information in Prevention and Treatment was a great way to avoid walls and walls of text as some of the other groups have done clearly identifying the cons of certain ‘current’ treatment methods. The amount of references that went into making this wikipage is a clear indication of how much effort was put in to making this page what it is&lt;br /&gt;
&lt;br /&gt;
Great job on the project so far!! Only thing I can say is to try look for a video regarding Female infertility!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
I would like to say great work of find substantial information and images to go along with your wikipage. From the table of contents there seems to be a lot of topics being addressed and with your use of subheadings, it makes navigating the page much easier. The short introduction described the basic meaning of male infertility well as well as the inclusion of some basic statistics is a nice bit of information however it would be nice to have some information regarding what your wikipage will be covering in general&lt;br /&gt;
&lt;br /&gt;
The background information is very useless as it provides the reader with some basic knowledge of where the male reproductive system and its components come into play in regard to the topic of male infertility. The images used are all referenced appropriately and assists in understanding where each component is located and what they look like. The tabulated data of the different types of male infertility allows the readers to easily understand the different kinds and what their relative symptoms are easily. Good job on that! The use of video is nice to see, it has relevance to your topic.&lt;br /&gt;
&lt;br /&gt;
Regarding information within the section ‘Major Causes of Infertility’, the information provided is awesome, however there just seems to be too much information crammed into small paragraphs which makes it quite draining to read. There are many terms which some readers may not know or understand, so I recommend using a glossary to help sort this problem out  maybe simplify the information (if you can)  or break up into more paragraphs to make it easier to read and digest. There are some sections which have no information, however I know that these will be filled by the submission date. The large amount of references is indicative of how much work went into the wikipage for your group! &lt;br /&gt;
&lt;br /&gt;
Good work guys!!&lt;br /&gt;
&lt;br /&gt;
''' Group 5 '''&lt;br /&gt;
&lt;br /&gt;
Great work so far on your wikipage guys, even just at first glance it is clear how much research and work was put in to make this page what it is. The amount of information that has been provided on the page is quite substantial. Within the contents table at the top of the page, each section has been broken down accordingly allowing ease of navigation for those who wish to know more about Oncofertility. The introduction provides us with a nice description of what Oncofertility is as well as a definition of the term ‘infertility’ which is helpful to those who do not know much information regarding the terms&lt;br /&gt;
&lt;br /&gt;
I think that some information can be split up into more paragraphs, especially information in the subheading ‘Radiation’, currently it is just a wall of text which makes it extremely hard to focus and understand all the words. Seeing as it is a procedure, maybe someone can include a hand-drawn image of the process and how affects the body?&lt;br /&gt;
&lt;br /&gt;
Information in the other sections are well organised and provides useful relevant information as well as providing deeper knowledge into certain techniques, chemicals and cancer cells in general. The information is a good addition (for both cancer cells and chemotherapy  however there is no referencing available to be found for both your videos. I think more images (hand-drawn or from other resources) need to be added to balance out the amount of text you have on your page.&lt;br /&gt;
&lt;br /&gt;
The overall structure other than the main subheadings that you currently have could be improved as some sections are just too long and cover a too broad information to be just kept under one subheading. Make use of more dot points to summarise the information. The table under Fertility preservation in women was concise and provides easy to read data, however the colouring of the background makes it hard to distinguish where each section of the box finishes and ends (maybe I’m colour-blind). I also think that it might be helpful to add a glossary to the bottom of your wikipage as there are quite a lot of terms that people may not understand &lt;br /&gt;
&lt;br /&gt;
Overall great work on your wikipage, I look forward to reading the final version!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
Skimming through the page, it is clear that a lot of research has been done to make this page what it is, each subheading is well thought out (maybe a overdone a bit by the additional sub-subheadings) and allows a transition. However there is a crucial part of the page is missing, the introduction. By not having an introduction at the beginning of the page, the project just jumps straight into information giving no clues as to what the project will be covering overall. It would be nice to have a concise definition of Artificial Reproductive Technologies (maybe replace ‘ART’ for the full word for the wikipage heading) The history has some nice information, but I think it can be improved by making use of tables or a graph for each of the dates, or even dot points to break the constant text.&lt;br /&gt;
&lt;br /&gt;
Overall in the other sections, the pictures are nice and are references appropriately and the use of table is nice (might be a bit dark to see the writing clearly). I think that some of the information can be broken up into small paragraphs rather than having one paragraph with around 30~40 sentences as it breaks down the information into easily digestible parts considering the amount of information which has been provided. &lt;br /&gt;
&lt;br /&gt;
The advantages and disadvantages of ART have been mentioned clearly without using lots of text, it makes the information easy to understand. I also think that more images are needed considering the widespread nature of the topic you have chosen, maybe some hand drawn images for those which you cannot find copyright information or a video to explain some of the procedures. Some grammar and formatting should be done before final submission to ensure that all sections are uniform in their font and sizing.&lt;br /&gt;
&lt;br /&gt;
Great work on finding all the information and making this page so far!! Good luck&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment ==&lt;br /&gt;
&lt;br /&gt;
'''[https://embryology.med.unsw.edu.au/embryology/Slides/Embryo_Stages/Stage22/08-eye/Stage22-08-eye.html?zoom=5&amp;amp;lat=-2259.81863&amp;amp;lon=4843.06006&amp;amp;layers=B Cillary Body]'''&lt;br /&gt;
&lt;br /&gt;
The cillary body is the section of the eye which houses the cillary muscle, which works to control the shape of the lens, and also the cillary epithelium, which produces the aqueous humor. It is a circular thickening of the walls within the eyes which divides the vitreous body from the posterior chamber. The inner layer is transparent and continuous with the neural tissues of the retina whilst the outer layer is highly pigmented and runs continuous with the retinal pigment epithelium and forms the cells of the dilator muscle.&lt;br /&gt;
&lt;br /&gt;
'''Embryology Link''' [[Vision - Retina Development#Retinal Pigment Epithelium]]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26244658&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
Look at this aye &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26244657&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;References/&amp;gt;&lt;br /&gt;
[[Test student 2015]]&lt;br /&gt;
{{StudentPage2015}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209643</id>
		<title>User:Z3374116</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=209643"/>
		<updated>2015-10-29T14:53:40Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 17:18, 5 August 2015 (AEST) Note your student number is already blue, as you have been previously enrolled in this course.&lt;br /&gt;
&lt;br /&gt;
Resource Investigator&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 13:45, 7 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:12, 14 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:08, 21 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:16, 11 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:26, 18 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:44, 25 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:13, 9 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:35, 16 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 23 October 2015 - Forgot to log attendance (heart formation lab where you went though our projects and said it was too pink)&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 1==&lt;br /&gt;
&lt;br /&gt;
'''Article 1'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26260201&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This article was written in aims to evaluate a prospectively implemented clinical algorithm which served in the early identifications of Ectopic pregnancy (EP) and Heterotopic pregnancy (HP) after use of assisted reproductive technologies (In-vitro fertilization). The data used in this research were patients who all received in-vitro fertilization or other methods of Assisted reproductive technology from between January 1995 to June 2013. &lt;br /&gt;
&lt;br /&gt;
The early pregnancy stage was monitored using clinical algorithms where all pregnancies were screened using Human chorionic gonadotropin (hCG) levels and any reported symptoms during pregnancy as well as use of ultrasound evaluations where hCG levels were abnormal or patient reported any pains.&lt;br /&gt;
&lt;br /&gt;
The research found that within the 3904 pregnancies included in the data, the incidence of Ectopic and Heterotopic pregnancies were 0.77% and 0.46% respectively. The clinical algorithm managed to detect and select 96.7% of the 0.77% diagnosed with EP as well as 83.3% of the 0.46% diagnosed with HP leading to earlier treatment and resolution of the problem. These results showed the effectiveness of the developed clinical algorithm in the early identification and prompt intervention of EP and HP bypassing the catastrophic morbidity associated with delayed diagnosis&lt;br /&gt;
&lt;br /&gt;
'''Article 2'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;24939956&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
	The article researched the effects of different levels of progesterone on the day of human gonadotropin administration in the live birth delivery rates during in-vitro fertilization. Previous researches have shown that the presence of late follicular phase progesterone is essential for follicular development, ovulation and endometrial receptivity. Studies were carried out on 2723 cycles performed in patients aged between 19 ~35 years of age and undergoing controlled ovarian stimulation.&lt;br /&gt;
&lt;br /&gt;
	The patients underwent ovarian stimulation using a gonadotropin releasing hormone antagonist for pituitary down-regulation and then final oocyte maturation was triggered using hCG 36h before oocyte retrieval. On the day of hCG administration, progesterone evaluation was performed and live birth delivery rates were compared at regular progesterone intervals.&lt;br /&gt;
&lt;br /&gt;
	The study found that live birth rates were significantly lower in patients with bow low (&amp;lt;0.5 ng/ml) and high (&amp;gt;1.5 ng/ml) late follicular progesterone levels.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:09, 4 September 2015 (AEST) These are good summaries of the 2 papers with correct reference format. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 2 ==&lt;br /&gt;
&lt;br /&gt;
[[File:Biopsy of Morula Stage Embryo.png|700px]]&lt;br /&gt;
&lt;br /&gt;
'''Biopsy of a Morula Stage Embryo'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25191937&amp;lt;/pubmed&amp;gt;|[http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106433]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:10, 4 September 2015 (AEST) Image uploaded correctly with reference, copyright and student template. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 3 ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26246873&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:11, 4 September 2015 (AEST) These 3 references relate to your project topic. It would have been good to include even just a single sentence explaining why you selected these 3. (4/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 4 - Quiz ==&lt;br /&gt;
&lt;br /&gt;
=== Mesoderm Development ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Cells which migrate from '''somites''' form: &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Respiratory System&lt;br /&gt;
- Smooth Muscles&lt;br /&gt;
- Digestive System&lt;br /&gt;
+ Skeletal Muscles&lt;br /&gt;
- Reproductive System&lt;br /&gt;
|| '''Somites arise from the Paraxial Mesoderm and give rise to skeletal muscles as well as other musculoskeletal structures'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Fertilization ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Which of the following statements are '''INCORRECT''' regarding Implantation? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Implantation commences at day 6 ~ 7&lt;br /&gt;
+ The blastocyst rolls along the uterine wall to align the inner cell mass furthest from the uterine epithelium&lt;br /&gt;
- Implantation is the process in which a blastocyst enters the uterine wall&lt;br /&gt;
- A coagulation plug forms where the blastocyst has entered the uterine wall&lt;br /&gt;
|| '''The blastocyst initially rolls down the uterine walls aligning the inner cell mass to be closest to the uterine epithelium before implantation occurs. After the blastocyst has entered the Uterine wall, a coagulation plug forms at the site of implantation'''&lt;br /&gt;
&lt;br /&gt;
{At which of the following layers does Implantation occur? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Myometrium&lt;br /&gt;
- Spongy layer of Endometrium&lt;br /&gt;
- Perimetrium&lt;br /&gt;
+ Compact layer of Endometrium&lt;br /&gt;
- Implantation layer of Endometrium&lt;br /&gt;
|| '''Implantation occurs in the Compact layer of Endometrium containing  dense stromal cells, uterine gland necks and capillaries of spiral arteries'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:12, 4 September 2015 (AEST) 3 questions here please. I will assess after the lab today.&lt;br /&gt;
&lt;br /&gt;
[[ANAT2341 Student 2015 Quiz Questions]]&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 5 ==&lt;br /&gt;
&lt;br /&gt;
'''What is the difference between Gastroschisis and Omphalocele?'''&lt;br /&gt;
&lt;br /&gt;
Omphalocele is fetal defect (occurring 1 in every 4000 births) which is defined as the herniation of the abdominal viscera into the umbilical cord. In this abdominal wall defect, internal abdominal organs such as the intestines, liver protrude outside of the belly via the belly button where the organs are covered by a thin, opaque sac which separates the internal organs with the fluids in the amniotic sac during pregnancy. The occurrence of Omphalocele is due to the incorrect or incomplete development of the muscles of the abdominal wall. &lt;br /&gt;
&lt;br /&gt;
Gastroschisis is a defect which is thought to have been caused due to the interruption of blood supply to the developing abdominal wall from the omphalomesenteric duct artery in the 8th week of gestation. Unlike Omphalocele occurring from the belly button, it is characterized by an extra-umbilical herniation of internal abdominal organs at the junction of umbilicus and normal skin (beside the belly button) and not enclosed in visceral peritoneum. &lt;br /&gt;
&lt;br /&gt;
Omphalocele develops in the 9th week of development when the intestines do not re-enter the body cavity whereas Gastroschisis arises within the 6th ~ 7th week of development when the abdominal wall muscles of the baby do not develop properly&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''&amp;lt;pubmed&amp;gt;2932813&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;12130917&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;15305094&amp;lt;/pubmed&amp;gt;'''&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 7==&lt;br /&gt;
'''1. Identify and write a brief description of the findings of a recent research paper on development of one of the endocrine organs covered in today's practical.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''2. Identify the embryonic layers and tissues that contribute to the developing teeth.'''&lt;br /&gt;
&lt;br /&gt;
Tooth development (Odontogenesis) begins in the 6th week of embryonic development and is made up of ectoderm, mesoderm and neural crest ectomesenchyme&lt;br /&gt;
&lt;br /&gt;
-	'''Ameloblasts''': derived from the epithelium of ectoderm cells from the 1st pharyngeal arch which produces the enamel. Enamel covers the crown of the tooth and are only found to be present during the process of odontogenesis&lt;br /&gt;
&lt;br /&gt;
-	'''Odontoblasts''': ectomesenchymal cells derived from the neural crest. These cells begin by forming the predentin which later hardens to become dentin&lt;br /&gt;
&lt;br /&gt;
==Peer Reviews==&lt;br /&gt;
&lt;br /&gt;
'''Group 1'''&lt;br /&gt;
&lt;br /&gt;
From first glance of the page, just by looking at the contents table found at the top of the wikipage, I can already see that all the sections have been planned and well thought out with the appropriate subheadings and sub-subheadings which makes the page a lot easier to navigate if I were to be searching for something in particular on the topic ‘Three Person Embryo’&lt;br /&gt;
&lt;br /&gt;
The introduction is short and concise with the appropriate description of what the topic is about, adding the YouTube video in your introduction was a great touch (props to you for asking the maker permission to re-use as it’s under the YouTube Standard License) however I think this section could be improved by maybe addressing the key points that the wiki page will be covering&lt;br /&gt;
&lt;br /&gt;
It’s great to see some history behind the development and progression of ‘Mitochondrial’ Donation throughout the years!! Is there any more history regarding this topic or is 1997 the first date with historical records?? Tabulation of the data may clean up this section, but otherwise great find!&lt;br /&gt;
&lt;br /&gt;
Under the benefits section, no actual benefits seems to have been listed? I think this section has not yet been completed&lt;br /&gt;
&lt;br /&gt;
The pictures and information under the ‘Technical Progression’ subheading is substantial and informative. The images seem to have been referenced and labelled accordingly but not sure if they are reusable as the sites / locations you obtained them from do not mention permission rights for reuse of their material. Some of the referencing done still shows the blue PMID which disrupts the flow of the project page.&lt;br /&gt;
&lt;br /&gt;
It is clear that a lot of research has been done into making this page what it is currently. I would suggest firstly to check that all material used on your page is re-useable as well as fixing up the minor coding of references and also grammar and spelling mistakes throughout the page. Great work!!&lt;br /&gt;
&lt;br /&gt;
'''Group 3'''&lt;br /&gt;
&lt;br /&gt;
Straight away I was impressed by the images and the table of contents. It appears that all subheadings are relevant and well planned. Having the definition in the introduction was great as well as the addition of epidemiology including the map, however I think it would be much more informative for readers if you touched on the variety of topics your wikipage will be covering (if they did not bother to read the table of contents)&lt;br /&gt;
&lt;br /&gt;
The variety of causes which are mentioned for Female infertility was concise and very informative under their respective sub-subheadings and with the appropriate referencing. There is a substantial amount of information provided under the ‘Pathogenesis’ section which clearly defines the different types, however, it seems that rather than Female infertility you have focused more information on ‘PCOS’ rather than all round? The images added in this heading was great in breaking up the text and the addition of animal and cell culture models were a really nice addition&lt;br /&gt;
&lt;br /&gt;
The signs and symptoms section is nice and simple while giving the reader all the necessary information without lines and lines of text which makes the information easy to access however in a section of ‘Diagnosis’, I think use of paragraphing may help the reader take rests to understand the large amount of information provided in the blood testing, maybe make use of a glossary for the bolded words. Other than that the image has been reference properly and the subheadings were helpful&lt;br /&gt;
&lt;br /&gt;
The tabulated information in Prevention and Treatment was a great way to avoid walls and walls of text as some of the other groups have done clearly identifying the cons of certain ‘current’ treatment methods. The amount of references that went into making this wikipage is a clear indication of how much effort was put in to making this page what it is&lt;br /&gt;
&lt;br /&gt;
Great job on the project so far!! Only thing I can say is to try look for a video regarding Female infertility!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
I would like to say great work of find substantial information and images to go along with your wikipage. From the table of contents there seems to be a lot of topics being addressed and with your use of subheadings, it makes navigating the page much easier. The short introduction described the basic meaning of male infertility well as well as the inclusion of some basic statistics is a nice bit of information however it would be nice to have some information regarding what your wikipage will be covering in general&lt;br /&gt;
&lt;br /&gt;
The background information is very useless as it provides the reader with some basic knowledge of where the male reproductive system and its components come into play in regard to the topic of male infertility. The images used are all referenced appropriately and assists in understanding where each component is located and what they look like. The tabulated data of the different types of male infertility allows the readers to easily understand the different kinds and what their relative symptoms are easily. Good job on that! The use of video is nice to see, it has relevance to your topic.&lt;br /&gt;
&lt;br /&gt;
Regarding information within the section ‘Major Causes of Infertility’, the information provided is awesome, however there just seems to be too much information crammed into small paragraphs which makes it quite draining to read. There are many terms which some readers may not know or understand, so I recommend using a glossary to help sort this problem out  maybe simplify the information (if you can)  or break up into more paragraphs to make it easier to read and digest. There are some sections which have no information, however I know that these will be filled by the submission date. The large amount of references is indicative of how much work went into the wikipage for your group! &lt;br /&gt;
&lt;br /&gt;
Good work guys!!&lt;br /&gt;
&lt;br /&gt;
''' Group 5 '''&lt;br /&gt;
&lt;br /&gt;
Great work so far on your wikipage guys, even just at first glance it is clear how much research and work was put in to make this page what it is. The amount of information that has been provided on the page is quite substantial. Within the contents table at the top of the page, each section has been broken down accordingly allowing ease of navigation for those who wish to know more about Oncofertility. The introduction provides us with a nice description of what Oncofertility is as well as a definition of the term ‘infertility’ which is helpful to those who do not know much information regarding the terms&lt;br /&gt;
&lt;br /&gt;
I think that some information can be split up into more paragraphs, especially information in the subheading ‘Radiation’, currently it is just a wall of text which makes it extremely hard to focus and understand all the words. Seeing as it is a procedure, maybe someone can include a hand-drawn image of the process and how affects the body?&lt;br /&gt;
&lt;br /&gt;
Information in the other sections are well organised and provides useful relevant information as well as providing deeper knowledge into certain techniques, chemicals and cancer cells in general. The information is a good addition (for both cancer cells and chemotherapy  however there is no referencing available to be found for both your videos. I think more images (hand-drawn or from other resources) need to be added to balance out the amount of text you have on your page.&lt;br /&gt;
&lt;br /&gt;
The overall structure other than the main subheadings that you currently have could be improved as some sections are just too long and cover a too broad information to be just kept under one subheading. Make use of more dot points to summarise the information. The table under Fertility preservation in women was concise and provides easy to read data, however the colouring of the background makes it hard to distinguish where each section of the box finishes and ends (maybe I’m colour-blind). I also think that it might be helpful to add a glossary to the bottom of your wikipage as there are quite a lot of terms that people may not understand &lt;br /&gt;
&lt;br /&gt;
Overall great work on your wikipage, I look forward to reading the final version!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
Skimming through the page, it is clear that a lot of research has been done to make this page what it is, each subheading is well thought out (maybe a overdone a bit by the additional sub-subheadings) and allows a transition. However there is a crucial part of the page is missing, the introduction. By not having an introduction at the beginning of the page, the project just jumps straight into information giving no clues as to what the project will be covering overall. It would be nice to have a concise definition of Artificial Reproductive Technologies (maybe replace ‘ART’ for the full word for the wikipage heading) The history has some nice information, but I think it can be improved by making use of tables or a graph for each of the dates, or even dot points to break the constant text.&lt;br /&gt;
&lt;br /&gt;
Overall in the other sections, the pictures are nice and are references appropriately and the use of table is nice (might be a bit dark to see the writing clearly). I think that some of the information can be broken up into small paragraphs rather than having one paragraph with around 30~40 sentences as it breaks down the information into easily digestible parts considering the amount of information which has been provided. &lt;br /&gt;
&lt;br /&gt;
The advantages and disadvantages of ART have been mentioned clearly without using lots of text, it makes the information easy to understand. I also think that more images are needed considering the widespread nature of the topic you have chosen, maybe some hand drawn images for those which you cannot find copyright information or a video to explain some of the procedures. Some grammar and formatting should be done before final submission to ensure that all sections are uniform in their font and sizing.&lt;br /&gt;
&lt;br /&gt;
Great work on finding all the information and making this page so far!! Good luck&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment ==&lt;br /&gt;
&lt;br /&gt;
'''[https://embryology.med.unsw.edu.au/embryology/Slides/Embryo_Stages/Stage22/08-eye/Stage22-08-eye.html?zoom=5&amp;amp;lat=-2259.81863&amp;amp;lon=4843.06006&amp;amp;layers=B Cillary Body]'''&lt;br /&gt;
&lt;br /&gt;
The cillary body is the section of the eye which houses the cillary muscle, which works to control the shape of the lens, and also the cillary epithelium, which produces the aqueous humor. It is a circular thickening of the walls within the eyes which divides the vitreous body from the posterior chamber. The inner layer is transparent and continuous with the neural tissues of the retina whilst the outer layer is highly pigmented and runs continuous with the retinal pigment epithelium and forms the cells of the dilator muscle.&lt;br /&gt;
&lt;br /&gt;
'''Embryology Link''' [[Vision - Retina Development#Retinal Pigment Epithelium]]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26244658&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
Look at this aye &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26244657&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;References/&amp;gt;&lt;br /&gt;
[[Test student 2015]]&lt;br /&gt;
{{StudentPage2015}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg&amp;diff=208649</id>
		<title>File:Vaginal Ultrasonography in Sagittal Plane.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg&amp;diff=208649"/>
		<updated>2015-10-23T13:07:21Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Vaginal Ultrasonography of OHSS patient(Sagittal) */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Vaginal Ultrasonography of OHSS patient(Sagittal)==&lt;br /&gt;
&lt;br /&gt;
Image showing the vaginal ultrasonography, sagittal section, of a woman who has been diagnosed with mild ovarian hyper-stimulation syndrome. &lt;br /&gt;
Fluid from the ovaries has filled the recto-uterine pouch.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762.&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
This file is made available under the Creative Commons CC0 1.0 Universal Public Domain Dedication. The person who associated a work with this deed has dedicated the work to the public domain by waiving all of his or her rights to the work worldwide under copyright law, including all related and neighboring rights, to the extent allowed by law. You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission.&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Abdominal_Paracentesis.png&amp;diff=208647</id>
		<title>File:Abdominal Paracentesis.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Abdominal_Paracentesis.png&amp;diff=208647"/>
		<updated>2015-10-23T13:06:39Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Abdominal Paracentesis */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Abdominal Paracentesis==&lt;br /&gt;
Paracentesis is a common procedure done on women who have OHSS as it is used to drain the ascites in their abdomen. In this image you can see the puncture of the peritoneal cavity with a needle that then drains the fluid externally&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Blausen.com staff. &amp;quot;Blausen gallery 2014&amp;quot;. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
The image was uploaded under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208245</id>
		<title>File:FSHR Gene.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208245"/>
		<updated>2015-10-23T03:19:47Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* FSHR Gene */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==FSHR Gene==&lt;br /&gt;
Cytogenic Location: 2p21-p16&lt;br /&gt;
&lt;br /&gt;
Molecular Location on Chromosome 2: base pairs 48,866,434 to 49,154,526&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
This image was based on the image found on the 'Genetic Home Reference' ''http://ghr.nlm.nih.gov/gene/FSHR'' website regarding the location of the FSHR gene&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
&amp;quot;Beginning six months after publication, I z3374116 grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208243</id>
		<title>File:FSHR Gene.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208243"/>
		<updated>2015-10-23T03:19:07Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* FSHR Gene */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==FSHR Gene==&lt;br /&gt;
Cytogenic Location: 2p21-p16&lt;br /&gt;
&lt;br /&gt;
Molecular Location on Chromosome 2: base pairs 48,866,434 to 49,154,526&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
This image was based on the image found on the 'Genetic Home Reference'[http://ghr.nlm.nih.gov/gene/FSHR] website regarding the location of the FSHR gene&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
&amp;quot;Beginning six months after publication, I z3374116 grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208241</id>
		<title>File:FSHR Gene.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208241"/>
		<updated>2015-10-23T03:18:25Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==FSHR Gene==&lt;br /&gt;
Cytogenic Location: 2p21-p16&lt;br /&gt;
&lt;br /&gt;
Molecular Location on Chromosome 2: base pairs 48,866,434 to 49,154,526&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
This image was =based on the image found on the 'Genetic Home Reference'[http://ghr.nlm.nih.gov/gene/FSHR] website regarding the location of the FSHR gene&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
&amp;quot;Beginning six months after publication, I z3374116 grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208237</id>
		<title>File:FSHR Gene.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208237"/>
		<updated>2015-10-23T03:13:54Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* FSHR Gene */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==FSHR Gene==&lt;br /&gt;
Cytogenic Location: 2p21-p16&lt;br /&gt;
Molecular Location on Chromosome 2: base pairs 48,866,434 to 49,154,526&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
This image was =based on the image found on the 'Genetic Home Reference'[http://ghr.nlm.nih.gov/gene/FSHR] website regarding the location of the FSHR gene&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
&amp;quot;Beginning six months after publication, I z3374116 grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208235</id>
		<title>File:FSHR Gene.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208235"/>
		<updated>2015-10-23T03:13:28Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==FSHR Gene==&lt;br /&gt;
Cytogenic Location: 2p21-p16&lt;br /&gt;
Molecular Location on Chromosome 2: base pairs 48,866,434 to 49,154,526&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
This image was =based on the image found on the 'Genetic Home Reference'[http://ghr.nlm.nih.gov/gene/FSHR] website regarding the location of the FSHR gene&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208233</id>
		<title>File:FSHR Gene.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208233"/>
		<updated>2015-10-23T03:12:52Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===FSHR Gene===&lt;br /&gt;
Cytogenic Location: 2p21-p16&lt;br /&gt;
Molecular Location on Chromosome 2: base pairs 48,866,434 to 49,154,526&lt;br /&gt;
&lt;br /&gt;
==Reference==&lt;br /&gt;
This image was based on the image found on the 'Genetic Home Reference'[http://ghr.nlm.nih.gov/gene/FSHR] website regarding the location of the FSHR gene&lt;br /&gt;
&lt;br /&gt;
==Copyright==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208227</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208227"/>
		<updated>2015-10-23T03:10:19Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Follicle Stimulating Hormome */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;'''This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it'''.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! colspan=4|Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
===&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;Classifications of Ovarian Hyper-stimulation Syndrome:&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;===&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
[[File:Abdominal Paracentesis.png|thumb|right|350px|Paracentesis is a common procedure done on women who have OHSS as it is used to drain the ascites in their abdomen. In this image you can see the puncture of the peritoneal cavity with a needle that then drains the fluid externally. &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Blausen.com staff. &amp;quot;Blausen gallery 2014&amp;quot;. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762 &amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
[[File:FSHR Gene.jpg|centre|thumbnail|700px|Location of the FSHR Gene]]&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''Oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208225</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208225"/>
		<updated>2015-10-23T03:09:11Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Follicle Stimulating Hormome */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;'''This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it'''.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! colspan=4|Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
===&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;Classifications of Ovarian Hyper-stimulation Syndrome:&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;===&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
[[File:Abdominal Paracentesis.png|thumb|right|350px|Paracentesis is a common procedure done on women who have OHSS as it is used to drain the ascites in their abdomen. In this image you can see the puncture of the peritoneal cavity with a needle that then drains the fluid externally. &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Blausen.com staff. &amp;quot;Blausen gallery 2014&amp;quot;. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762 &amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
[[File:FSHR Gene.jpg|Thumbnail|centre|Location of the FSHR Gene]]&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''Oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208223</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208223"/>
		<updated>2015-10-23T03:08:30Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Follicle Stimulating Hormome */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;'''This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it'''.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! colspan=4|Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
===&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;Classifications of Ovarian Hyper-stimulation Syndrome:&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;===&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
[[File:Abdominal Paracentesis.png|thumb|right|350px|Paracentesis is a common procedure done on women who have OHSS as it is used to drain the ascites in their abdomen. In this image you can see the puncture of the peritoneal cavity with a needle that then drains the fluid externally. &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Blausen.com staff. &amp;quot;Blausen gallery 2014&amp;quot;. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762 &amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
[[File:FSHR Gene.jpg|Thumb|centre|Location of the FSHR Gene]]&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''Oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208219</id>
		<title>File:FSHR Gene.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:FSHR_Gene.jpg&amp;diff=208219"/>
		<updated>2015-10-23T03:07:18Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: ==FSHR Gene==&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==FSHR Gene==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208121</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208121"/>
		<updated>2015-10-23T02:37:50Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Treatment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;'''This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it'''.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! colspan=4|Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
===&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;Classifications of Ovarian Hyper-stimulation Syndrome:&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;===&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
[[File:Abdominal Paracentesis.png|thumb|right|350px|Illustration depicting Paracentesis &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Blausen.com staff. &amp;quot;Blausen gallery 2014&amp;quot;. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762 &amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208113</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208113"/>
		<updated>2015-10-23T02:36:00Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Treatment */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;'''This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it'''.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! colspan=4|Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
===&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;Classifications of Ovarian Hyper-stimulation Syndrome:&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;===&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
[[File:Abdominal Paracentesis.png|thumb|right|350px|Illustration depicting Paracentesis]]&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208105</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208105"/>
		<updated>2015-10-23T02:34:49Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Paracentesis */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;'''This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it'''.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! colspan=4|Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
===&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;Classifications of Ovarian Hyper-stimulation Syndrome:&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;===&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
[[File:Abdominal Paracentesis.png|thumb|right|350px|Illustration depicting Paracentesis]]&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Abdominal_Paracentesis.png&amp;diff=208089</id>
		<title>File:Abdominal Paracentesis.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Abdominal_Paracentesis.png&amp;diff=208089"/>
		<updated>2015-10-23T02:32:51Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===Reference===&lt;br /&gt;
&lt;br /&gt;
Blausen.com staff. &amp;quot;Blausen gallery 2014&amp;quot;. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
The image was uploaded using the Creative Commons Copyright which provides freedom to copy and redistribute the material in any medium or format and adapt in any means or purpose as long as appropriate credit is given.&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Abdominal_Paracentesis.png&amp;diff=208085</id>
		<title>File:Abdominal Paracentesis.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Abdominal_Paracentesis.png&amp;diff=208085"/>
		<updated>2015-10-23T02:32:34Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: ===Reference===

Blausen.com staff. &amp;quot;Blausen gallery 2014&amp;quot;. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762

===Copyright===
The image was uploaded using the Creative Commons Copyright which provides freedom to copy and redist...&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===Reference===&lt;br /&gt;
&lt;br /&gt;
Blausen.com staff. &amp;quot;Blausen gallery 2014&amp;quot;. Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
The image was uploaded using the Creative Commons Copyright which provides freedom to copy and redistribute the material in any medium or format and adapt in any means or purpose as long as appropriate credit is given.&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208023</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=208023"/>
		<updated>2015-10-23T02:20:36Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Epidemiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! colspan=4|Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''''Classifications of Ovarian Hyper-stimulation Syndrome:'''''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207979</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207979"/>
		<updated>2015-10-23T02:01:03Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Current Research on Animal Models */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''''Classifications of Ovarian Hyper-stimulation Syndrome:'''''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Polycystic_Ovaries.jpeg&amp;diff=207977</id>
		<title>File:Polycystic Ovaries.jpeg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Polycystic_Ovaries.jpeg&amp;diff=207977"/>
		<updated>2015-10-23T02:00:16Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Normal Ovary vs Polycystic Ovary==&lt;br /&gt;
&lt;br /&gt;
Image depicting the difference of a Normal ovary (Top) and a Polycystic ovary (Bottom)&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
'''U.S Department of Health and Human Services,  Office of Women's Health '''[http://www.womenshealth.gov/publications/our-publications/fact-sheet/polycystic-ovary-syndrome.html] ' ''Polycystic Ovary Syndrome (PCOS) fact sheet'' ' - Accessed on 23 October 2015&lt;br /&gt;
&lt;br /&gt;
===Copyright===&lt;br /&gt;
&lt;br /&gt;
The information on our website is provided by the U.S. federal government and is in the public domain. This public information is not copyrighted and may be reproduced without permission, though citation of each source is appreciated.&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg&amp;diff=207975</id>
		<title>File:Vaginal Ultrasonography in Sagittal Plane.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg&amp;diff=207975"/>
		<updated>2015-10-23T01:57:56Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Vaginal Ultrasonography of OHSS patient(Sagittal)==&lt;br /&gt;
&lt;br /&gt;
Image showing the vaginal ultrasonography, sagittal section, of a woman who has been diagnosed with mild ovarian hyper-stimulation syndrome. &lt;br /&gt;
Fluid from the ovaries has filled the recto-uterine pouch.&lt;br /&gt;
&lt;br /&gt;
===Reference===&lt;br /&gt;
Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762.&lt;br /&gt;
&lt;br /&gt;
====Copyright====&lt;br /&gt;
This file is made available under the Creative Commons CC0 1.0 Universal Public Domain Dedication. The person who associated a work with this deed has dedicated the work to the public domain by waiving all of his or her rights to the work worldwide under copyright law, including all related and neighboring rights, to the extent allowed by law. You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission.&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Pathogenesis_of_OHSS.png&amp;diff=207973</id>
		<title>File:Pathogenesis of OHSS.png</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Pathogenesis_of_OHSS.png&amp;diff=207973"/>
		<updated>2015-10-23T01:56:57Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;br /&gt;
==Pathogenesis of OHSS==&lt;br /&gt;
&lt;br /&gt;
After stimulation with exogenous and endogenous hCG and FSH, multiple follicles are stimulated. These follicles then secrete VEGF which act on mutated VEGF receptors of vessel walls, increasing their permeability. As a result, fluid leaks from these vessels into the abdominal cavities causing ascites.&lt;br /&gt;
===Reference===&lt;br /&gt;
&lt;br /&gt;
Based upon the image by Peter Humaidan, Jens Quartarolo and Evangelos G. Papanikolaou &amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
===Copyright===&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Beginning six months after publication, I z3374116 grant the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
{{Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207971</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207971"/>
		<updated>2015-10-23T01:55:28Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Pathophysiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''''Classifications of Ovarian Hyper-stimulation Syndrome:'''''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Polycystic_Ovaries.jpeg&amp;diff=207965</id>
		<title>File:Polycystic Ovaries.jpeg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Polycystic_Ovaries.jpeg&amp;diff=207965"/>
		<updated>2015-10-23T01:53:49Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;'''Normal Ovary vs Polycystic Ovary'''&lt;br /&gt;
&lt;br /&gt;
Image depicting the difference of a Normal ovary and a Polycystic ovary&lt;br /&gt;
&lt;br /&gt;
'''Reference'''&lt;br /&gt;
&lt;br /&gt;
'''U.S Department of Health and Human Services,  Office of Women's Health '''[http://www.womenshealth.gov/publications/our-publications/fact-sheet/polycystic-ovary-syndrome.html] ' ''Polycystic Ovary Syndrome (PCOS) fact sheet'' ' - Accessed on 23 October 2015&lt;br /&gt;
&lt;br /&gt;
'''Copyright'''&lt;br /&gt;
&lt;br /&gt;
The information on our website is provided by the U.S. federal government and is in the public domain. This public information is not copyrighted and may be reproduced without permission, though citation of each source is appreciated.&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Polycystic_Ovaries.jpeg&amp;diff=207957</id>
		<title>File:Polycystic Ovaries.jpeg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Polycystic_Ovaries.jpeg&amp;diff=207957"/>
		<updated>2015-10-23T01:46:14Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;'''Normal Ovary vs Polycystic Ovary'''&lt;br /&gt;
&lt;br /&gt;
Image depicting the difference of a Normal ovary and a Polycystic ovary&lt;br /&gt;
&lt;br /&gt;
'''Reference'''&lt;br /&gt;
{{cite web |url=http://www.womenshealth.gov/publications/our-publications/fact-sheet/polycystic-ovary-syndrome.html |title=Polycystic Ovary Syndrome (PCOS) fact sheet |publisher=U.S Department of Heath and Human Services |access-date=23 October 2015}}&lt;br /&gt;
&lt;br /&gt;
'''Copyright'''&lt;br /&gt;
The information on our website is provided by the U.S. federal government and is in the public domain. This public information is not copyrighted and may be reproduced without permission, though citation of each source is appreciated.&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207941</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207941"/>
		<updated>2015-10-23T01:40:55Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Pathophysiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|centre|thumb|Pathogenesis of OHSS- after stimulation with exogenous and endogenous hCG and FSH, multiple follicles are stimulated. These follicles then secrete VEGF which act on mutated VEGF receptors of vessel walls, increasing their permeability. As a result, fluid leaks from these vessels into the abdominal cavities causing ascites. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207937</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207937"/>
		<updated>2015-10-23T01:39:21Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Complications */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women with OHSS by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS- after stimulation with exogenous and endogenous hCG and FSH, multiple follicles are stimulated. These follicles then secrete VEGF which act on mutated VEGF receptors of vessel walls, increasing their permeability. As a result, fluid leaks from these vessels into the abdominal cavities causing ascites. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. [[File:Polycystic Ovaries.jpeg|right|thumbnail|360px|Comparison of Normal and Polycystic Ovary]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Polycystic_Ovaries.jpeg&amp;diff=207925</id>
		<title>File:Polycystic Ovaries.jpeg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Polycystic_Ovaries.jpeg&amp;diff=207925"/>
		<updated>2015-10-23T01:32:39Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: Image depicting the difference of a normal ovary and a polycystic ovary&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Image depicting the difference of a normal ovary and a polycystic ovary&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207917</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207917"/>
		<updated>2015-10-23T01:25:31Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Current Research on Animal Models */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS- after stimulation with exogenous and endogenous hCG and FSH, multiple follicles are stimulated. These follicles then secrete VEGF which act on mutated VEGF receptors of vessel walls, increasing their permeability. As a result, fluid leaks from these vessels into the abdominal cavities causing ascites. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FFF5FF&amp;quot; &lt;br /&gt;
|&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207913</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207913"/>
		<updated>2015-10-23T01:18:09Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Current Research on Animal Models */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Follicular Development.jpeg|right|thumbnail|500px|Infertility treatments aim to facilitate follicular development and induce ovulation to improve chances of fertilisation &amp;lt;ref name=&amp;quot;PMID24717179&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24717179&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs (as shown in the diagram to the right), further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to '''oligouria''' &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS- after stimulation with exogenous and endogenous hCG and FSH, multiple follicles are stimulated. These follicles then secrete VEGF which act on mutated VEGF receptors of vessel walls, increasing their permeability. As a result, fluid leaks from these vessels into the abdominal cavities causing ascites. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who undergo ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypovolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone '''Controlled Ovarian Stimulation''' (COS).&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*Previous history of OHSS. &lt;br /&gt;
*High pretreatment basal Anti-Mullerian Hormone (AMH) concentration&lt;br /&gt;
*Large Antral Follicle Count (AFC)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through '''Aromatase Inhibitors''' which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI.&amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt; During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists '''GnRHa''' are administered in addition to gonadotropins. Alternatively, '''GnRH antagonists''' may be administered to downregulate endogenous LH secretion. Comparative studies have shown that the GnRH antagonist protocol has a greater effect in lowering the incidence of mild to severe OHSS. However due to the rare nature of OHSS, and insufficient sample sizes, the difference was not found to be significant. &amp;lt;ref name=&amp;quot;PMID21082508&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082508&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Generally, the duration of exposure to gonadotropins and subsequent risk of OHSS may be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63%.&amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
Women who develop OHSS while undergoing Assisted Reproductive Technologies (ART) treatment are not only more likely to achieve a pregnancy, but have a live birth as the pregnancy outcome. This live birth is also more likely to be a multiple birth of two, three or more children. &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; It has been postulated that a multi-fetal pregnancy leads to a more rapid increase in hCG levels, resulting in an increased risk of OHSS. However, the causal nature between multi-fetal pregnancy and OHSS development is disputed and further research is required to distinguish correlation from causation. &amp;lt;ref name=&amp;quot;PMID19573292&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573292&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS development is also associated with an increased risk of adverse outcomes including '''stillbirth, premature birth and low birth weight'''.&amp;lt;ref name=&amp;quot;PMID19591989&amp;quot; /&amp;gt; Although the cause for the increased risk in adverse pregnancy outcomes is unknown, it is suggested that as the incidence of OHSS is reduced through various prevention strategies, the risk of such outcomes may be also be reduced.&lt;br /&gt;
&lt;br /&gt;
[[http://pregnancyperfect.com/emilyley/ The following link is to a podcast of a woman describing her pregnancy in which she underwent IVF, had OHSS and gave birth to healthy twins]]&amp;lt;ref name=&amp;quot;Emily&amp;quot;&amp;gt; Pregnancy Perfect[ http://pregnancyperfect.com/emilyley/ ], 'TWINS, IVF, OHSS AND C-SECTION WITH EMILY LEY'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26 &lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Aromatase Inhibitor''' - A drug that inhibits enzyme aromatase, which in turn suppresses estrogen synthesis.&lt;br /&gt;
&lt;br /&gt;
'''Ascites''' - An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling.&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''Controlled Ovarian Stimulation''' - female infertility treatment using medications to stimulate the ovaries to develop follicles. &lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation''' - Cooling and storing biological material at extremely low temperatures.&lt;br /&gt;
&lt;br /&gt;
'''E2''' - Estradiol - Potent estrogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''Gonadotropin''' - Any hormone that has a stimulating effect on the gonads. &lt;br /&gt;
&lt;br /&gt;
'''GnRH agonist''' - Gonadotropin Releasing Hormone - A class of compounds that mimic the effect of the natural Gonadotropin Releasing Hormone.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration''' - An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume.&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic''' - A decrease in circulating blood volume.&lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic''' - Illness caused as a result of a medical examination or treatment. &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF''' - In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Metformin''' - A biguanide, antidiabetic drug used as an adjuvant to modify the effect of other agents.&lt;br /&gt;
&lt;br /&gt;
'''NSAID''' - Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''oocyte vitrification''' - technique for cryopreservation of oocytes.&lt;br /&gt;
&lt;br /&gt;
'''OHSS''' - Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced.&lt;br /&gt;
&lt;br /&gt;
'''P4''' - Progesterone - endogenous progestogen sex hormone.&lt;br /&gt;
&lt;br /&gt;
'''PCOS''' - Polycystic Ovarian Syndrome. An endrocrine system disorder whereby the ovaries are enlarged with small collections of fluid.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=207703</id>
		<title>User:Z3374116</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3374116&amp;diff=207703"/>
		<updated>2015-10-22T18:03:25Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 17:18, 5 August 2015 (AEST) Note your student number is already blue, as you have been previously enrolled in this course.&lt;br /&gt;
&lt;br /&gt;
Resource Investigator&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 13:45, 7 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:12, 14 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:08, 21 August 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:16, 11 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:26, 18 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:44, 25 September 2015 (AEST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:13, 9 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3374116|Z3374116]] ([[User talk:Z3374116|talk]]) 12:35, 16 October 2015 (AEDT)&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 1==&lt;br /&gt;
&lt;br /&gt;
'''Article 1'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26260201&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This article was written in aims to evaluate a prospectively implemented clinical algorithm which served in the early identifications of Ectopic pregnancy (EP) and Heterotopic pregnancy (HP) after use of assisted reproductive technologies (In-vitro fertilization). The data used in this research were patients who all received in-vitro fertilization or other methods of Assisted reproductive technology from between January 1995 to June 2013. &lt;br /&gt;
&lt;br /&gt;
The early pregnancy stage was monitored using clinical algorithms where all pregnancies were screened using Human chorionic gonadotropin (hCG) levels and any reported symptoms during pregnancy as well as use of ultrasound evaluations where hCG levels were abnormal or patient reported any pains.&lt;br /&gt;
&lt;br /&gt;
The research found that within the 3904 pregnancies included in the data, the incidence of Ectopic and Heterotopic pregnancies were 0.77% and 0.46% respectively. The clinical algorithm managed to detect and select 96.7% of the 0.77% diagnosed with EP as well as 83.3% of the 0.46% diagnosed with HP leading to earlier treatment and resolution of the problem. These results showed the effectiveness of the developed clinical algorithm in the early identification and prompt intervention of EP and HP bypassing the catastrophic morbidity associated with delayed diagnosis&lt;br /&gt;
&lt;br /&gt;
'''Article 2'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;24939956&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
	The article researched the effects of different levels of progesterone on the day of human gonadotropin administration in the live birth delivery rates during in-vitro fertilization. Previous researches have shown that the presence of late follicular phase progesterone is essential for follicular development, ovulation and endometrial receptivity. Studies were carried out on 2723 cycles performed in patients aged between 19 ~35 years of age and undergoing controlled ovarian stimulation.&lt;br /&gt;
&lt;br /&gt;
	The patients underwent ovarian stimulation using a gonadotropin releasing hormone antagonist for pituitary down-regulation and then final oocyte maturation was triggered using hCG 36h before oocyte retrieval. On the day of hCG administration, progesterone evaluation was performed and live birth delivery rates were compared at regular progesterone intervals.&lt;br /&gt;
&lt;br /&gt;
	The study found that live birth rates were significantly lower in patients with bow low (&amp;lt;0.5 ng/ml) and high (&amp;gt;1.5 ng/ml) late follicular progesterone levels.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:09, 4 September 2015 (AEST) These are good summaries of the 2 papers with correct reference format. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 2 ==&lt;br /&gt;
&lt;br /&gt;
[[File:Biopsy of Morula Stage Embryo.png|700px]]&lt;br /&gt;
&lt;br /&gt;
'''Biopsy of a Morula Stage Embryo'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25191937&amp;lt;/pubmed&amp;gt;|[http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0106433]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:10, 4 September 2015 (AEST) Image uploaded correctly with reference, copyright and student template. (5/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 3 ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26246873&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:11, 4 September 2015 (AEST) These 3 references relate to your project topic. It would have been good to include even just a single sentence explaining why you selected these 3. (4/5)&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 4 - Quiz ==&lt;br /&gt;
&lt;br /&gt;
=== Mesoderm Development ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Cells which migrate from '''somites''' form: &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Respiratory System&lt;br /&gt;
- Smooth Muscles&lt;br /&gt;
- Digestive System&lt;br /&gt;
+ Skeletal Muscles&lt;br /&gt;
- Reproductive System&lt;br /&gt;
|| '''Somites arise from the Paraxial Mesoderm and give rise to skeletal muscles as well as other musculoskeletal structures'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Fertilization ===&lt;br /&gt;
&lt;br /&gt;
&amp;lt;quiz display=simple&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{Which of the following statements are '''INCORRECT''' regarding Implantation? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Implantation commences at day 6 ~ 7&lt;br /&gt;
+ The blastocyst rolls along the uterine wall to align the inner cell mass furthest from the uterine epithelium&lt;br /&gt;
- Implantation is the process in which a blastocyst enters the uterine wall&lt;br /&gt;
- A coagulation plug forms where the blastocyst has entered the uterine wall&lt;br /&gt;
|| '''The blastocyst initially rolls down the uterine walls aligning the inner cell mass to be closest to the uterine epithelium before implantation occurs. After the blastocyst has entered the Uterine wall, a coagulation plug forms at the site of implantation'''&lt;br /&gt;
&lt;br /&gt;
{At which of the following layers does Implantation occur? &lt;br /&gt;
|type=&amp;quot;()&amp;quot;}&lt;br /&gt;
- Myometrium&lt;br /&gt;
- Spongy layer of Endometrium&lt;br /&gt;
- Perimetrium&lt;br /&gt;
+ Compact layer of Endometrium&lt;br /&gt;
- Implantation layer of Endometrium&lt;br /&gt;
|| '''Implantation occurs in the Compact layer of Endometrium containing  dense stromal cells, uterine gland necks and capillaries of spiral arteries'''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/quiz&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z8600021|Mark Hill]] ([[User talk:Z8600021|talk]]) 11:12, 4 September 2015 (AEST) 3 questions here please. I will assess after the lab today.&lt;br /&gt;
&lt;br /&gt;
[[ANAT2341 Student 2015 Quiz Questions]]&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment 5 ==&lt;br /&gt;
&lt;br /&gt;
'''What is the difference between Gastroschisis and Omphalocele?'''&lt;br /&gt;
&lt;br /&gt;
Omphalocele is fetal defect (occurring 1 in every 4000 births) which is defined as the herniation of the abdominal viscera into the umbilical cord. In this abdominal wall defect, internal abdominal organs such as the intestines, liver protrude outside of the belly via the belly button where the organs are covered by a thin, opaque sac which separates the internal organs with the fluids in the amniotic sac during pregnancy. The occurrence of Omphalocele is due to the incorrect or incomplete development of the muscles of the abdominal wall. &lt;br /&gt;
&lt;br /&gt;
Gastroschisis is a defect which is thought to have been caused due to the interruption of blood supply to the developing abdominal wall from the omphalomesenteric duct artery in the 8th week of gestation. Unlike Omphalocele occurring from the belly button, it is characterized by an extra-umbilical herniation of internal abdominal organs at the junction of umbilicus and normal skin (beside the belly button) and not enclosed in visceral peritoneum. &lt;br /&gt;
&lt;br /&gt;
Omphalocele develops in the 9th week of development when the intestines do not re-enter the body cavity whereas Gastroschisis arises within the 6th ~ 7th week of development when the abdominal wall muscles of the baby do not develop properly&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''&amp;lt;pubmed&amp;gt;2932813&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;12130917&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
&amp;lt;pubmed&amp;gt;15305094&amp;lt;/pubmed&amp;gt;'''&lt;br /&gt;
&lt;br /&gt;
==Lab Assessment 7==&lt;br /&gt;
'''1. Identify and write a brief description of the findings of a recent research paper on development of one of the endocrine organs covered in today's practical.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''2. Identify the embryonic layers and tissues that contribute to the developing teeth.'''&lt;br /&gt;
&lt;br /&gt;
Tooth development (Odontogenesis) begins in the 6th week of embryonic development and is made up of ectoderm, mesoderm and neural crest ectomesenchyme&lt;br /&gt;
&lt;br /&gt;
-	'''Ameloblasts''': derived from the epithelium of ectoderm cells from the 1st pharyngeal arch which produces the enamel. Enamel covers the crown of the tooth and are only found to be present during the process of odontogenesis&lt;br /&gt;
&lt;br /&gt;
-	'''Odontoblasts''': ectomesenchymal cells derived from the neural crest. These cells begin by forming the predentin which later hardens to become dentin&lt;br /&gt;
&lt;br /&gt;
==Peer Reviews==&lt;br /&gt;
&lt;br /&gt;
'''Group 1'''&lt;br /&gt;
&lt;br /&gt;
From first glance of the page, just by looking at the contents table found at the top of the wikipage, I can already see that all the sections have been planned and well thought out with the appropriate subheadings and sub-subheadings which makes the page a lot easier to navigate if I were to be searching for something in particular on the topic ‘Three Person Embryo’&lt;br /&gt;
&lt;br /&gt;
The introduction is short and concise with the appropriate description of what the topic is about, adding the YouTube video in your introduction was a great touch (props to you for asking the maker permission to re-use as it’s under the YouTube Standard License) however I think this section could be improved by maybe addressing the key points that the wiki page will be covering&lt;br /&gt;
&lt;br /&gt;
It’s great to see some history behind the development and progression of ‘Mitochondrial’ Donation throughout the years!! Is there any more history regarding this topic or is 1997 the first date with historical records?? Tabulation of the data may clean up this section, but otherwise great find!&lt;br /&gt;
&lt;br /&gt;
Under the benefits section, no actual benefits seems to have been listed? I think this section has not yet been completed&lt;br /&gt;
&lt;br /&gt;
The pictures and information under the ‘Technical Progression’ subheading is substantial and informative. The images seem to have been referenced and labelled accordingly but not sure if they are reusable as the sites / locations you obtained them from do not mention permission rights for reuse of their material. Some of the referencing done still shows the blue PMID which disrupts the flow of the project page.&lt;br /&gt;
&lt;br /&gt;
It is clear that a lot of research has been done into making this page what it is currently. I would suggest firstly to check that all material used on your page is re-useable as well as fixing up the minor coding of references and also grammar and spelling mistakes throughout the page. Great work!!&lt;br /&gt;
&lt;br /&gt;
'''Group 3'''&lt;br /&gt;
&lt;br /&gt;
Straight away I was impressed by the images and the table of contents. It appears that all subheadings are relevant and well planned. Having the definition in the introduction was great as well as the addition of epidemiology including the map, however I think it would be much more informative for readers if you touched on the variety of topics your wikipage will be covering (if they did not bother to read the table of contents)&lt;br /&gt;
&lt;br /&gt;
The variety of causes which are mentioned for Female infertility was concise and very informative under their respective sub-subheadings and with the appropriate referencing. There is a substantial amount of information provided under the ‘Pathogenesis’ section which clearly defines the different types, however, it seems that rather than Female infertility you have focused more information on ‘PCOS’ rather than all round? The images added in this heading was great in breaking up the text and the addition of animal and cell culture models were a really nice addition&lt;br /&gt;
&lt;br /&gt;
The signs and symptoms section is nice and simple while giving the reader all the necessary information without lines and lines of text which makes the information easy to access however in a section of ‘Diagnosis’, I think use of paragraphing may help the reader take rests to understand the large amount of information provided in the blood testing, maybe make use of a glossary for the bolded words. Other than that the image has been reference properly and the subheadings were helpful&lt;br /&gt;
&lt;br /&gt;
The tabulated information in Prevention and Treatment was a great way to avoid walls and walls of text as some of the other groups have done clearly identifying the cons of certain ‘current’ treatment methods. The amount of references that went into making this wikipage is a clear indication of how much effort was put in to making this page what it is&lt;br /&gt;
&lt;br /&gt;
Great job on the project so far!! Only thing I can say is to try look for a video regarding Female infertility!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
I would like to say great work of find substantial information and images to go along with your wikipage. From the table of contents there seems to be a lot of topics being addressed and with your use of subheadings, it makes navigating the page much easier. The short introduction described the basic meaning of male infertility well as well as the inclusion of some basic statistics is a nice bit of information however it would be nice to have some information regarding what your wikipage will be covering in general&lt;br /&gt;
&lt;br /&gt;
The background information is very useless as it provides the reader with some basic knowledge of where the male reproductive system and its components come into play in regard to the topic of male infertility. The images used are all referenced appropriately and assists in understanding where each component is located and what they look like. The tabulated data of the different types of male infertility allows the readers to easily understand the different kinds and what their relative symptoms are easily. Good job on that! The use of video is nice to see, it has relevance to your topic.&lt;br /&gt;
&lt;br /&gt;
Regarding information within the section ‘Major Causes of Infertility’, the information provided is awesome, however there just seems to be too much information crammed into small paragraphs which makes it quite draining to read. There are many terms which some readers may not know or understand, so I recommend using a glossary to help sort this problem out  maybe simplify the information (if you can)  or break up into more paragraphs to make it easier to read and digest. There are some sections which have no information, however I know that these will be filled by the submission date. The large amount of references is indicative of how much work went into the wikipage for your group! &lt;br /&gt;
&lt;br /&gt;
Good work guys!!&lt;br /&gt;
&lt;br /&gt;
''' Group 5 '''&lt;br /&gt;
&lt;br /&gt;
Great work so far on your wikipage guys, even just at first glance it is clear how much research and work was put in to make this page what it is. The amount of information that has been provided on the page is quite substantial. Within the contents table at the top of the page, each section has been broken down accordingly allowing ease of navigation for those who wish to know more about Oncofertility. The introduction provides us with a nice description of what Oncofertility is as well as a definition of the term ‘infertility’ which is helpful to those who do not know much information regarding the terms&lt;br /&gt;
&lt;br /&gt;
I think that some information can be split up into more paragraphs, especially information in the subheading ‘Radiation’, currently it is just a wall of text which makes it extremely hard to focus and understand all the words. Seeing as it is a procedure, maybe someone can include a hand-drawn image of the process and how affects the body?&lt;br /&gt;
&lt;br /&gt;
Information in the other sections are well organised and provides useful relevant information as well as providing deeper knowledge into certain techniques, chemicals and cancer cells in general. The information is a good addition (for both cancer cells and chemotherapy  however there is no referencing available to be found for both your videos. I think more images (hand-drawn or from other resources) need to be added to balance out the amount of text you have on your page.&lt;br /&gt;
&lt;br /&gt;
The overall structure other than the main subheadings that you currently have could be improved as some sections are just too long and cover a too broad information to be just kept under one subheading. Make use of more dot points to summarise the information. The table under Fertility preservation in women was concise and provides easy to read data, however the colouring of the background makes it hard to distinguish where each section of the box finishes and ends (maybe I’m colour-blind). I also think that it might be helpful to add a glossary to the bottom of your wikipage as there are quite a lot of terms that people may not understand &lt;br /&gt;
&lt;br /&gt;
Overall great work on your wikipage, I look forward to reading the final version!! Good luck!&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
Skimming through the page, it is clear that a lot of research has been done to make this page what it is, each subheading is well thought out (maybe a overdone a bit by the additional sub-subheadings) and allows a transition. However there is a crucial part of the page is missing, the introduction. By not having an introduction at the beginning of the page, the project just jumps straight into information giving no clues as to what the project will be covering overall. It would be nice to have a concise definition of Artificial Reproductive Technologies (maybe replace ‘ART’ for the full word for the wikipage heading) The history has some nice information, but I think it can be improved by making use of tables or a graph for each of the dates, or even dot points to break the constant text.&lt;br /&gt;
&lt;br /&gt;
Overall in the other sections, the pictures are nice and are references appropriately and the use of table is nice (might be a bit dark to see the writing clearly). I think that some of the information can be broken up into small paragraphs rather than having one paragraph with around 30~40 sentences as it breaks down the information into easily digestible parts considering the amount of information which has been provided. &lt;br /&gt;
&lt;br /&gt;
The advantages and disadvantages of ART have been mentioned clearly without using lots of text, it makes the information easy to understand. I also think that more images are needed considering the widespread nature of the topic you have chosen, maybe some hand drawn images for those which you cannot find copyright information or a video to explain some of the procedures. Some grammar and formatting should be done before final submission to ensure that all sections are uniform in their font and sizing.&lt;br /&gt;
&lt;br /&gt;
Great work on finding all the information and making this page so far!! Good luck&lt;br /&gt;
&lt;br /&gt;
== Lab Assessment ==&lt;br /&gt;
&lt;br /&gt;
'''[https://embryology.med.unsw.edu.au/embryology/Slides/Embryo_Stages/Stage22/08-eye/Stage22-08-eye.html?zoom=5&amp;amp;lat=-2259.81863&amp;amp;lon=4843.06006&amp;amp;layers=B Cillary Body]'''&lt;br /&gt;
&lt;br /&gt;
The cillary body is the section of the eye which houses the cillary muscle, which works to control the shape of the lens, and also the cillary epithelium, which produces the aqueous humor. It is a circular thickening of the walls within the eyes which divides the vitreous body from the posterior chamber. The inner layer is transparent and continuous with the neural tissues of the retina whilst the outer layer is highly pigmented and runs continuous with the retinal pigment epithelium and forms the cells of the dilator muscle.&lt;br /&gt;
&lt;br /&gt;
'''Embryology Link''' [[Vision - Retina Development#Retinal Pigment Epithelium]]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;pubmed&amp;gt;26244658&amp;lt;/pubmed&amp;gt;&lt;br /&gt;
Look at this aye &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26244657&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;References/&amp;gt;&lt;br /&gt;
[[Test student 2015]]&lt;br /&gt;
{{StudentPage2015}}&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207697</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207697"/>
		<updated>2015-10-22T17:43:55Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Ovarian Hyper-stimulation Syndrome (OHSS) */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Ovarian Hyper-stimulation Syndrome (OHSS)'''&amp;lt;/span&amp;gt;== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FF99FF&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207693</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207693"/>
		<updated>2015-10-22T17:36:48Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Current Research on Animal Models */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FF99FF&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production. Using Immature Wistar rats (22 days old) as their animal model, the rats were initially stimulated with Gonadotrophins to mimic the onset and effects of OHSS and then subjected to treatment with a D2-agonist and/or a D2-antagonist (D2-ant). The vascular permeability was measured at the endpoint after day 26 by measuring the peritoneal extravasion of a previously injected dye and ovaries from all subjects were collected to assess the effects of D2-ag and D2-ant on the production of Ovarian VEGF. The expression of VEGF mRNA was measured by quantitative real time PCR and the levels of VEGF proteins were measured by Western Blots.&lt;br /&gt;
&lt;br /&gt;
Results showed that the D2-ag caused a large reduction in the vascular permeability which was in turn associated with the great decreased in VEGF protein production in the OHSS rat ovaries, whereas the introduction of D2-ant showed opposite results with a increase in the vascular permeability leading to the increase of VEGF protein production in the ovaries. Ovarian VEGF mRNA levels were found to be unaffected by the introduction of these drugs in OHSS rat subjects. Conclusions were drawn on the fact that Dopamine Receptor 2 agonists prevent the increase of vascular permeability in subjects with OHSS by decreasing the ovarian production of VEGF and also that due to the dose-dependent inhibitory effect of the D2-ag on ovarian VEGF, current OHSS therapies used in humans can benefit by increasing the intraovarian concentration of D2-ag.&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207689</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207689"/>
		<updated>2015-10-22T17:24:04Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Current Research on Animal Models */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FF99FF&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID25217874&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25217874&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production&lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207687</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207687"/>
		<updated>2015-10-22T17:23:23Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Current Research on Animal Models */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;FF99FF&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Ovarian VEGF secretion by activation of Dopamine Receptor 2'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
This research was carried out to investigate a possibility in whether a Dopamine Receptor 2 agonist '''(D2-ag)''' can assist in the prevention of Ovarian Hyperstimulation Syndrome, using rat models, by decreasing the ovarian vascular endothelial growth factor '''(VEGF)''' production&lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207681</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207681"/>
		<updated>2015-10-22T17:08:52Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Animal Models */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Current Research on Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:120%&amp;quot;&amp;gt;'''Inhibition of Cyclooxygenase-2 (COX-2) by Meloxican decreasing the incidence of OHSS in Rat Model'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID18166186&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;18166186&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Reasearch was carried out to investigate the effects of selective inhibition of the enzyme COX-2 on the Ovarian Hyperstimulation Syndrome (OHSS) using Female Wistar rates as the subjects.  The research aimed to find results by measuring the number of antral and luteinized follicles, ovarian weight, vascualr endothelial growth factors and COX-2 immunohistochemistry. The rats being tested were all 22 days old and were divided into four equal groups; &lt;br /&gt;
&lt;br /&gt;
'''Group 1 (Control group)''' was subject to a 0.1 ml of Intraperitoneal Saline from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
'''Group 2 (Mildly-stimulated group)''' subject to 10IU of pregnant mare serum gonadotrophin (PMSG) on day 24 and then 10IU of Human Chorionic Gonadotrophin (hCG) on day 26 &lt;br /&gt;
&lt;br /&gt;
'''Group 3 (OHSS positive group)''' was subject to 10IU of PMSG from days 22 ~ 26 and then administered 30IU of hCG on day 26 to induce OHSS &lt;br /&gt;
&lt;br /&gt;
'''Group 4 (OHSS positive variant group)''' received 15mg/ml of Meloxicam 2 hours prior to administration of 10IU PMSG from days 22 ~ 26&lt;br /&gt;
&lt;br /&gt;
Results showed there was no difference in ovarian weight in samples from Group 1 and Group 2, however Group 3 showed signs of significant ovarian weight increase which in group 4 was suppressed by the introduction of Meloxicam. No differences were observed in the number of antral follicles amongst the four test groups. Results from Group 2 and Group 3 showed that the granulosa cells of preovulatory follicles and the stromal cells were highly VEGF immunoreactive, however the Meloxicam treated Group 4 showed less immunoreactivity than Group 2 and Group 3 which indicated the correlation between Meloxicam and the diminished VEGF expression. Group 3 presented an increased COS-2 immunoreactivity which was highly diminished than in Group 4.&lt;br /&gt;
&lt;br /&gt;
The research concluded that in a rat model, the enzyme Meloxicam has a beneficial effect on OHSS by reducing the increase of ovarian weight and the expression of VEGF associated with OHSS, the effects of which may be mediated by the inhibitory capacity of COX-2 on Meloxicam&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207679</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207679"/>
		<updated>2015-10-22T16:40:58Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Animal Models */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Current Tests using Rat Models&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207663</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207663"/>
		<updated>2015-10-22T13:23:54Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Complications */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; '''1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS''' &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207661</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207661"/>
		<updated>2015-10-22T13:22:09Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Epidemiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (Mean ± SD)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Maternal Age (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Nulligravida (%)'''&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| '''Infertility Diagnosis (%)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; 1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207655</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207655"/>
		<updated>2015-10-22T13:13:24Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Symptoms */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (Mean ± SD)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Nulligravida (%)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Infertility Diagnosis (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; 1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207653</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207653"/>
		<updated>2015-10-22T13:12:44Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Epidemiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (Mean ± SD)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Nulligravida (%)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Infertility Diagnosis (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; 1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207651</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207651"/>
		<updated>2015-10-22T13:10:39Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Epidemiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''No Complications &lt;br /&gt;
(N = 212,041)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS &lt;br /&gt;
(N = 1,523)'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; height=&amp;quot;60px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS &lt;br /&gt;
(N = 655)'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (Mean ± SD)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Nulligravida (%)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Infertility Diagnosis (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; 1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207649</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207649"/>
		<updated>2015-10-22T13:07:39Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Epidemiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed&amp;quot;&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; style=&amp;quot;text-align:center| '''No Complications'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;100px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (Mean ± SD)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Nulligravida (%)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Infertility Diagnosis (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:left; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; 1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207647</id>
		<title>2015 Group Project 2</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_2&amp;diff=207647"/>
		<updated>2015-10-22T13:03:35Z</updated>

		<summary type="html">&lt;p&gt;Z3374116: /* Epidemiology */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{ANAT2341Project2015header}}  &lt;br /&gt;
&lt;br /&gt;
==Ovarian Hyper-stimulation Syndrome (OHSS)== &lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper stimulation Syndrome (OHSS) is an iatrogenic complication of '''Assisted Reproduction Technology''' (ART), in which women take medications to stimulate oocyte growth. It is generally identified by cystic enlargements of the ovaries and fluid accumulation in the peritoneal cavity due to the increased capillary permeability and ovarian neoangiogenesis &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It is an occurrence which is dependent on the controlled stimulation of the ovaries in preparation for IVF i.e. administration of human Chorionic Gonadotropin (hCG). &lt;br /&gt;
&lt;br /&gt;
OHSS was first described in 1943 as ''“syndrome d’hyperluteinisation massive&lt;br /&gt;
des ovaries”''. It was during this time that gonadotropins were prepared from animals such as sheep to bring on ovulation in women. The first recorded death as a result of OHSS occurred in 1951 and was due to renal failure as a result of oligouria, a complication of the syndrome &amp;lt;ref name=&amp;quot;OHSS&amp;quot;&amp;gt; Marie M. Budev, DO, MPH; Alejandro C. Arroliga, MD; Tommaso Falcone, MD, [ http://utilis.net/Morning%20Topics/REI/Ovarian%20Hyperstimulation.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt;This wikipage aims to provide clear information on various areas surrounding OHSS such as diagnosis, prevention and complications and will look into the genetics behind the disorder and the various animals models used to research it.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;html5media height=&amp;quot;350&amp;quot; width=&amp;quot;450&amp;quot;&amp;gt;https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/html5media&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Overview of the Ovarian Hyperstimulation Syndrome''' &amp;lt;ref&amp;gt; Howcast (2013, August 27) Ovarian Hyperstimulation Syndrome | Infertility. Retrieved from https://www.youtube.com/watch?v=aXmjJw234a4&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian Hyper-Stimulation Syndrome (OHSS) rarely occurs sporadically, and if it does, it is usually the result of an underlying genetic problem. The majority of OHSS is due to the ovaries being stimulated to mature and release an abundance of oocytes, in response to hormones Human Chorionic Gonadotropin (hCG) and Follicle Stimulating hormone (FSH), during IVF. Rarely, Clomifene Citrate therapy can cause OHSS.&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot;&amp;gt; Wikipedia, [ https://en.wikipedia.org/wiki/Ovarian_hyperstimulation_syndrome ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS only affects '''0.5-5%''' of women undergoing Ovarian Hyper-stimulation, but despite its small prevalence, it is a potentially fatal outcome of a non-vital procedure and remains a prevalent problem for fertility specialists &amp;lt;ref name=&amp;quot;PMID12498425&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12498425&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;12638783&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Age has been cited as a factor affecting those with OHSS, with younger women more at risk. Additionally, women with allergies were seen to have a higher incidence of OHSS. It is important to note that at this point in time, there is no positive correlation between gonadotropin dose and OHSS.   &lt;br /&gt;
&lt;br /&gt;
Of the 0.5-5% of women affected with OHSS mentioned above, 2% of those women will require hospitalisation. As of 2011, it has been reported that the incidence of OHSS was '''increasing''', resulting in approximately 3 deaths per 100,000 women undergoing ovarian stimulation per year &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21828116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This is particularly worrying as in 2008, in the United States alone, there were around 150,000 IVF cycles undertaken.  &lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''With the field of Assisted Reproductive Technologies expanding and more women partaking in IVF treatments, the threat of women developing OHSS is an ongoing and increasing one''' &amp;lt;ref name=&amp;quot;PMID21828116&amp;quot; /&amp;gt;.&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible mw-collapsed; background: #F6CEEC&amp;quot;&lt;br /&gt;
&lt;br /&gt;
! Characteristics of women by complication group &amp;lt;ref name=&amp;quot;PMID19591989&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19591989&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
|- &lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;200px&amp;quot; style=&amp;quot;text-align:center| '''Characteristic'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;200px&amp;quot; style=&amp;quot;text-align:center| '''No Complications'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;200px&amp;quot; style=&amp;quot;text-align:center| '''Moderate OHSS'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;200px&amp;quot; style=&amp;quot;text-align:center| '''Severe OHSS'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (Mean ± SD)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 35.6 ± 4.6&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.0 ± 4.3&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.1 ± 4.4&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Maternal Age (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| &amp;lt;30 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.6 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| 30-34 years &lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 30.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 43.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 40.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| 35-39 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 27.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 32.5 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| &amp;gt;40 years&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 21.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 8.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 6.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Nulligravida (%)&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 45.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 51.8 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #FF99FF;&amp;quot;| Infertility Diagnosis (%)&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| Male factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 37.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 41.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 33.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| Endometriosis&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.7 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #FF99FF;&amp;quot;| Ovulation Disorders&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 14.0 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 29.5 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| Diminished ovarian reserve&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 16.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.2 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 2.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| Tubal factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 20.4 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.6 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 22.3 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| Uterine factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 5.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 4.3 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 3.1 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| Other factors&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.9 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 13.1 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 10.4 %&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:right; background: #F6CEEC;&amp;quot;| Unexplained factor&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 12.7 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 11.8 %&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| 18.6 %&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Causative Agents==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Normally a woman produces one egg per month from the ovaries, which travel down the Fallopian tube to be fertilized or be released from the body. In cases where women have difficulty falling pregnant, they are given medication which help them to produce and release eggs, further increasing their chances of fertilization and pregnancy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19573285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Ovarian Hyper stimulation Syndrome generally occurs during infertility treatments when the ovaries are overstimulated by the fertility medication which causes the ovaries to swell and leak fluids into the belly and abdomen. The prevalence of OHSS onset is linked with excessive number of follicle development in response to the administration of injectable Follicle Stimulating Hormones (FSH) followed by the '''Human Chorionic Gonadotrophins''' (hCG) which triggers the release of the oocytes &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;26190539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Follicle Stimulating Hormones''' (FSH) &amp;lt;ref name=&amp;quot;PMID9020850&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9020850&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; are glycoprotein hormones that are produced and secreted from the Anterior Pituitary gland into the bloodstream, which regulate the developmental, growth, maturation and the reproductive processes within the body. In females, the Follicle Stimulating Hormones initiates the stages of growth and development of immature ovarian follicles within the ovaries before the release of an egg from a follicle at ovulation. When FSH is administered to a patient who is suffering from infertility, the increase FSH levels affect the rate of development and production, in turn increasing the amount of follicles which are ready to be released during ovulation.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Symptoms==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
OHSS is classified based on a criteria from mild, moderate and severe &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
'''Mild Symptoms'''- abdominal bloating, minimal weight gain, nausea, diarrhoea and a feeling of fullness.&lt;br /&gt;
&lt;br /&gt;
'''Moderate Symptoms'''- Substantial weight gain (on average 2 or more pounds a day), increased abdominal girth, darkend urine and excessive thirst in addition to the mild symptoms. &lt;br /&gt;
&lt;br /&gt;
'''Severe Symptoms'''- In addition to the symptoms associated with Mild and Moderate OHSS, in severe OHSS, you see shortness of breath, calf and chest pains and pleural effusion.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-size:100%&amp;quot;&amp;gt;'''Classifications of Ovarian Hyper-stimulation Syndrome:'''&amp;lt;/span&amp;gt; &amp;lt;ref name=&amp;quot;PMID22065820&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22065820&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot; style=&amp;quot;text-align:center&lt;br /&gt;
|-&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;70px&amp;quot;| '''Classification'''&lt;br /&gt;
! scope=&amp;quot;col&amp;quot; width=&amp;quot;650px&amp;quot;| '''Symptoms'''&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Mild''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 1''' - Abdominal distention and discomfort&lt;br /&gt;
'''Grade 2''' - Abdominal distention, discomfort with nausea, vomiting and/or diarrhea and ovarian enlargement from 5~12cm&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F8E0F1;&amp;quot;| '''Moderate'''&lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F8E0F1;&amp;quot;| '''Grade 3''' - All features of Mild OHSS with ultrasonographic evidence of ascites&lt;br /&gt;
|-&lt;br /&gt;
|style=&amp;quot;text-align:center; background: #F6CEEC;&amp;quot;| '''Severe''' &lt;br /&gt;
|style=&amp;quot;height: 60px; background: #F6CEEC;&amp;quot;| '''Grade 4''' - All features of Moderate OHSS with the addition of clinical evidence of ascites and breathing difficulties present&lt;br /&gt;
'''Grade 5''' - All of the above symptoms along with a change in the blood volume, increased blood viscosity due to coagulation and diminished renal function&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Diagnosis==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Whilst symptoms of OHSS can occur as soon as 24 hours post hCG administration, they are usually seen in women 7-10 days post administration. Initially women with OHSS will present with abdominal bloating, as a result of fluid in the peritoneal cavity and an increase in ovary size.  When women present with severe OHSS they are often dehydrated, due to increased vascular permeability, and have hemoconcentration. The above results in a decrease in intravascular volume, leading to oligouria &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;.  &lt;br /&gt;
&lt;br /&gt;
===History===&lt;br /&gt;
&lt;br /&gt;
Initially a thorough history of the patient is taken during which the clinician looks for evidence of ovarian stimulation, followed by ovulation. During this history taking, the clinician will inquire into any weight gain noticed, urine output, and the woman's ability to maintain oral hydration. A key diagnostic tool for clinicians regarding women who are taking gonadotropins is to identify if they are at an increased risk of developing OHSS. Some risk factors include woman aged less than 30, women who have polycystic ovaries, woman with a previous history of OHSS and women who have had greater than 20 oocytes retrieved &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Physical Exam===&lt;br /&gt;
[[File:Vaginal_Ultrasonography_in_Sagittal_Plane.jpg|right|thumbnail|600px|Vaginal Ultrasonography in Sagittal plane &amp;lt;ref name=&amp;quot;Wikiversity Journal of Medicine&amp;quot;&amp;gt; Häggström, Mikael. &amp;quot;Medical gallery of Mikael Häggström 2014&amp;quot;. Wikiversity Journal of Medicine 1 (2). DOI:10.15347/wjm/2014.008. ISSN 20018762&amp;lt;/ref&amp;gt;]] &lt;br /&gt;
After a history of the patient is taken, the next step is to perform a physical exam on the patient. Women who present with abdominal bloating will produce a shifting dullness upon abdominal percussion. Additionally the clinician will test the woman's vital signs, measure her abdominal girth, weight and will look for evidence of ascites or increase in calf size (usually unilateral)&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
===Investigations===&lt;br /&gt;
&lt;br /&gt;
If the clinician further suspects a women of having OHSS, various investigations can be done such as an ultrasound.The intraperitoneal fluid is best imaged via vaginal ultrasound due to the enlarged ovaries making it difficult to image the pelvis using transabdominal ultrasound. The clinician can also order laboratory testing to look for urine specific gravity and and complete blood count to look for hemoconcentration with a hematocrit. Additionally, liver function tests can be ordered to look for elevated function. The clinician will also look for evidence of elevated D-dimers and fibrinogen and decreased levels of anti-thrombin 3 &amp;lt;ref name=&amp;quot;SAHealth&amp;quot;&amp;gt; Government of South Australia Health [ http://www.sahealth.sa.gov.au/wps/wcm/connect/9b61ed004ee5348da663afd150ce4f37/Ovarian-hyperstimulation-syndrome-WCHN-PPG-17072012.pdf?MOD=AJPERES&amp;amp;CACHEID=9b61ed004ee5348da663afd150ce4f37 ], 'South Australian Paediatric Clinical Guidelines OHSS'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
====Ultrasound====&lt;br /&gt;
&lt;br /&gt;
Typical appearances of the ultrasound include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot;&amp;gt; Radiopaedia [ http://radiopaedia.org/articles/ovarian-hyperstimulation-syndrome-1 ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Bilaterally and symmetrically enlarged ovaries (&amp;gt;12cm)&lt;br /&gt;
* &amp;quot;Spoke-Wheel appearance&amp;quot; - presence of multiple cysts of varying size &lt;br /&gt;
*May also see ascites (fluid)&lt;br /&gt;
&lt;br /&gt;
===Severity===&lt;br /&gt;
&lt;br /&gt;
Once a clinician has deduced a women is suffering from OHSS, the severity of their condition needs to be established as either mild, moderate or severe. This is done by referring to the criteria under the sub-heading [[Symptoms]].The subsequent course of treatment for the woman will be based upon this evaluation.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F6CEEC&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
'''Further investigations''' can be done including a Chest X-ray to check for pleural effusions and oedema and USS with Doppler's to check for ascites or possible ovary torsion. &amp;lt;ref name=&amp;quot;PMID22416285&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22416285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
Conditions presenting with similar symptoms or ultrasound images include &amp;lt;ref name=&amp;quot;Ultrasound&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Polycystic Ovaries (PO)&lt;br /&gt;
:: The difference is that with PO is that the cycts are typically smaller than OHSS cysts and there is no evidence of ascited or pleural effusion&lt;br /&gt;
*Mucinous Ovarian Malignancy &lt;br /&gt;
:: A type of Ovarian Epithelial tumour &lt;br /&gt;
*Ectopic Pregnancy &amp;lt;ref name=&amp;quot;Casereport&amp;quot;&amp;gt; Australian Medical Student Journal [ http://www.amsj.org/wpcontent/uploads/files/articles/amsj_v2_i1/AMSJ_v2_i1_pg58-60.pdf ], 'Ovarian hyperstimulation syndrome'&amp;lt;/ref&amp;gt;&lt;br /&gt;
::A pregnancy in which the foetus develops outside of the uterus e.g. in the fallopian tube&lt;br /&gt;
 &lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Pathophysiology==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis_of_OHSS.png|600px|thumb|Pathogenesis of OHSS &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
&lt;br /&gt;
The definition of Ovarian Stimulation is enlarged ovaries with many luteinized cysts, that can present with secondary complications. What distinguishes Ovarian Stimulation from OHSS is the presence of vascular hyper-permeability that results in fluids being redirected elsewhere in the body. &lt;br /&gt;
&lt;br /&gt;
The key process to OHSS appears to be caused by '''Vascular Endothelial Growth Factor''' (VEGF), that is released along with other cytokines, estrogen and progesterone, due to the ovary undergoing luteinization as a result of stimulation by hCG. VEGF increases vascular permeability and as a result the capillaries become more &amp;quot;leaky&amp;quot; to the fluids in them. These fluids can then escape the capillaries and accumulate in the pleural and abdominal cavities as ascites. The woman then becomes hypovolemic and is at an increased risk of circulatory, renal and respiratory issues such as arterial thromboembolism due to the thickening of the blood. Note, the blood is thickened as fluid is leaving the capillaries, leaving behind red blood cells and other cellular components of the blood &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The increase in expression of VEGF and VEGF Receptor 2 (VEGFR2) is attributed to the greatly increased amount of their mRNA present in the body after stimulation with hCG &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21082502&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. VEGF interacts with VEGF2 and VEGF Receptor 1 (VEGFR1) to create a strong angiogenic effect. Both VEGFR2 and VEGFR1 belong to a family of receptors called tyrosine kinases. VEGF2 is involved in the regulation of angiogenesis and vascular permeability whilst VEGF1 has a slightly contradictory role in that is is involved in the maintenance of the tight junctions between endothelial cells in blood vessels. A study by Gómez ''et. al.'' &amp;lt;ref name=&amp;quot;PMID21082502&amp;quot; /&amp;gt; showed that women experiencing OHSS had substantially higher plasma levels of VEGF and lower levels of VEGFR1.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Complications==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Ovarian torsion or rupture, renal insufficiency and thrombophlebitis can all complicate OHSS. If a pregnancy occurs, symptoms may persist longer than the usual 1 to 2 weeks and become more severe, however, even with severe OHSS, they do not extend past the first trimester &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color:#FA58D0&amp;quot;&amp;gt; 1-2% of women who suffer from ovarian stimulation develop a severe form of OHSS &amp;lt;/span&amp;gt;. Complications from severe OHSS include: &lt;br /&gt;
&lt;br /&gt;
*Fluid collection in the abdomen&lt;br /&gt;
*Electrolyte disturbances (sodium and potassium)     &lt;br /&gt;
*Kidney failure&lt;br /&gt;
*Ovary twisting&lt;br /&gt;
*Rupture of a cyst in an ovary&lt;br /&gt;
*Breathing problems&lt;br /&gt;
*Blood clots in large vessels (most commonly the legs)&lt;br /&gt;
*Pregnancy loss from miscarriage or termination&lt;br /&gt;
*Rarely, death&lt;br /&gt;
&lt;br /&gt;
A study by Nouri ''et. al.'' &amp;lt;ref name=&amp;quot;PMID24996451&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;24996451&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that women with '''Polycystic Ovarian Syndrome''' (PCOS) and those that were induced with hCG experienced longer recovery times from severe OHSS than women who were not pregnant. They looked at a cohort of women hospitalised for the first time with severe OHSS and subject them to the same treatments. Based on a defined criteria, they established the recovery time of these women and compared the times between those that were pregnant to those that were not pregnant. They also found that whether a woman had PCOS or ovulation induction did not affect her risk of developing OHSS if she was not pregnant. It is only a risk factor for pregnant women. &lt;br /&gt;
&lt;br /&gt;
===Thromboembolic events===&lt;br /&gt;
&lt;br /&gt;
A frequent and deadly complication of OHSS are thromboembolic events due to increased blood clotting. This increase in blood clotting has been attributed to a variety of complications such as hemoconcentration (which thickens the blood), hypolvolemia and an increase in the permeability of blood vessels as a result of increased vasoactive substances in the body of ovarian origin. Thromboembolic events include venous thromboses often in the upper extremities and arterial thromboses such as those in the cerebrovascular region. These events can lead to amputations of extremities, brain damage, miscarriage and death. To avoid this, anti-coagulants are given to pateitns with OHSS and they are fitted with compression stockings (see [[Treatment]]) &amp;lt;ref name=&amp;quot;PMID23378404&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23378404&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The risk of a woman developing OHSS is higher if she is having a '''twin pregnancy''', as she is exposed to higher concentration of hCG. &amp;lt;ref name=&amp;quot;PMID9756273&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;9756273&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''General treatment&lt;br /&gt;
'''&lt;br /&gt;
*''Acetaminophen'' with or without a narcotic agent- used to treat abdominal discomfort&lt;br /&gt;
*Women are encouraged to drink 2-3 litres of water a day to prevent hemoconcentration&lt;br /&gt;
*Women are advised to avoid sexual intercourse and vigorous exercise at the risk of torsion or rupture of the ovaries&lt;br /&gt;
*NSAID's with anti-platelet properties should NOT be used as they may effect renal function in a women with OHSS&lt;br /&gt;
*Patients with significantly painful ascites or breathing problems may undergo ''Paracentesis'' (drainage of the ascites)&lt;br /&gt;
*''Culdocentesis'' (extraction of fluid from recto-uterine pouch) can be done to decrease the likelihood of a woman with moderate OHSS progressing to severe OHSS.&amp;lt;ref name=&amp;quot;PMID22416285&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Mild to Moderate OHSS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Mild OHSS can often resolve on its own, however, moderate OHSS may include treatments such as&amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Anti-nausea medication and prescription painkillers&lt;br /&gt;
*Regular physical examinations and ultrasounds&lt;br /&gt;
*Daily weigh-ins and waist measurements&lt;br /&gt;
*Measuring the amount of urine produced each day&lt;br /&gt;
*Frequent blood tests for monitoring dehydration and electrolyte imbalance&lt;br /&gt;
*Maintaining a high balance of fluids&lt;br /&gt;
*Drainage of excess abdominal fluid by inserting a needle in the abdominal cavity&lt;br /&gt;
*Wearing support stockings which help prevent blood clots/thrombosis&lt;br /&gt;
&lt;br /&gt;
===Severe OHSS===&lt;br /&gt;
&lt;br /&gt;
Severe OHSS requires hospital care in order for constant monitoring and treatment such as &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Intravenous fluids with a crystalloid solution (100-150mL/hr) &lt;br /&gt;
*Intravenous Albumin is administered is IV fluids are insufficient (15-20mL/hr of 25% albumin for 4 hrs)&lt;br /&gt;
*In addition to Acetaminophen, ''Opioid analgesics'' can be administered for pain relief &lt;br /&gt;
*''Antiemetics'' can be used to subside nauseas and/or vomiting&lt;br /&gt;
*Woman administered to hospital of OHSS are considered at high risk of thromboembolic complications and are given low molecular weight ''heparin'', an anti-coagulant  &lt;br /&gt;
*''Cabergoline''- lessens OHSS symptoms&lt;br /&gt;
*''GnRH agonist''- suppresses ovarian activity&lt;br /&gt;
**If at risk of OHSS, alternates include using a GnRH agonist instead of hCG however its effects on pregnancy rates are questionable. Using a GnRH agonist to replace the use of hCG for final oocyte stimulation will see a 6% decrease in delivery rate. &lt;br /&gt;
&lt;br /&gt;
*Daily monitoring of creatine, urea, creatine clearance C-reactive protein (to rule out infection) are all required in combination with weekly tests such as liver and renal function tests and chest x-rays (to check for pleural effusion) &amp;lt;ref name=&amp;quot;PMID12638783&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
If there are serious complications then additional treatments are required:&lt;br /&gt;
&lt;br /&gt;
*Surgery for a ruptured ovarian cyst &lt;br /&gt;
*Intensive care for the liver or lung complications&lt;br /&gt;
&lt;br /&gt;
====Paracentesis====&lt;br /&gt;
&lt;br /&gt;
For women with severe/grade 3 OHSS, paracentesis, the removal of fluid from the body using an aspiration needle, can be undertaken. It is a diagnostic and a therapeutic method that can be done trans-abdominally and trans-vaginally. It is used to relieve symptoms, improve haemodynamics e.g. Urinary output, and shorten the women's hospital stay.  Complications of paracentesis include bleeding, infection and organ injury, however are note common &amp;lt;ref name=&amp;quot;Paracentesis&amp;quot;&amp;gt; S. Monica Soni, HMS 3, Gillian Lieberman, MD [ http://eradiology.bidmc.harvard.edu/LearningLab/genito/Soni.pdf ], 'Ovarian Hyperstimulation Syndrome'&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;F8E0F1&amp;quot; &lt;br /&gt;
|&lt;br /&gt;
The most important aspect of treatment for any women with OHSS is close and constant '''monitoring''' with her healthcare professional. Counselling may also be provided to women and their partners or families in order to provide them with the best possible knowledge base to manage and treat their OHSS. It is important to note that there is '''no one cure or treatment''' for OHSS. Treatment involves managing and eliminating the symptoms until such time as the syndrome resolves itself &amp;lt;ref name=&amp;quot;WikiOHSS&amp;quot; /&amp;gt;.&lt;br /&gt;
|} &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Prevention==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
There are three key avenues through which the incidence of OHSS may be prevented. These include identifying risk factors to predict OHSS development, modifying treatment regimes on the basis of the identified risk factors and intervention to prevent progression to OHSS once the patient has undergone Controlled Ovarian Stimulation.&lt;br /&gt;
&lt;br /&gt;
=== Risk factors===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Primary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Pre-existing factors likely to exacerbate the ovarian stimulation response. Primary risk factors include &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26074966&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*Young age &lt;br /&gt;
*Low body weight &lt;br /&gt;
*History of elevated response to gonadotropins &lt;br /&gt;
*Polycystic Ovary Syndrome (PCOS)&lt;br /&gt;
*Isolated PCOS characteristic &lt;br /&gt;
*A previous history of OHSS. &lt;br /&gt;
*Hormonal markers (e.g. Anti-Mullerian Hormone markers)&lt;br /&gt;
*Ultrasonographic markers (e.g. Antral Follicle Count)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Secondary risk factors'''&lt;br /&gt;
&lt;br /&gt;
Secondary risk factors involve the monitoring of ovarian response parameters once COS has been initiated. These parameters are monitored for &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19007627&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;:&lt;br /&gt;
&lt;br /&gt;
*rapidly rising E2 levels&lt;br /&gt;
*E2 concentration larger than 2500 pg/mL &lt;br /&gt;
*large number of developing follicles (10-14mm) on the day hCG is administered &lt;br /&gt;
*large number of oocytes retrieved&lt;br /&gt;
&lt;br /&gt;
These factors in combination, act as a predictive tool to assess the likelihood of severe OHSS development, with a 83% sensitivity and 84% specificity. &amp;lt;ref name=&amp;quot;PMID19007627&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Primary Prevention===&lt;br /&gt;
&lt;br /&gt;
Primary Prevention involves the modification of treatment regimens on the basis of OHSS risk classifications, in order to prevent OHSS occurrence. &lt;br /&gt;
&lt;br /&gt;
'''Ovulation Induction'''&lt;br /&gt;
&lt;br /&gt;
Unifollicular Ovulation Induction through Ovulation Induction (OI) is a primary means of avoiding OHSS in women with Polycystic Ovarian Syndrome, who are at an increased risk. In order to promote unifollicular development, the ovaries are stimulated with a low starting dose of FSH (75 IU).&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20416867&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies suggests that a minimum gonadotropin dose lowers OHSS risk and thus a step-up regimen is utilised to achieve an ovarian response, whereby the FSH dosage is increased every 7 days until follicular development of greater than 10mm is noted &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot; /&amp;gt;. Alternatively, a step-down regimen may be followed, whereby a high initial FSH dosage is lowered according to the ovarian response. Another method to increase FSH levels during OI, is through Aromatase Inhibitors which promote folliculogenesis by increasing pituitary secretion of FSH, and downregulate oestrogen production through a negative feedback loop. However, Aromatase Inhibitors have not been shown to reduce OHSS incidence in comparison to other methods of OI. During OI, a key objective is to prevent early cycle cancellation due to premature luteinisation from pituitary secretion of LH. In order to downregulate LH secretion, Gonadotropin-releasing hormone agonists (GnRHa) are administered in addition to gonadotropins. The duration of exposure to gonadotropins and subsequent risk of OHSS may also be minimised through mild stimulation protocols which administer FSH only in the mid to late follicular phase.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Adjuvant Metformin Therapy'''&lt;br /&gt;
&lt;br /&gt;
Adjuvant Metformin Therapy has been found to lower the risk of OHSS by 63% &amp;lt;ref name=&amp;quot;PMID25406011&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;25406011&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. It involves the administration of metformin at a daily dosage of 1000 to 2000mg, 2 months prior to Controlled Ovarian Stimulation &amp;lt;ref name=&amp;quot;PMID26074966&amp;quot;/&amp;gt;. Metformin lowers the elevated insulin levels in PCOS which consequently reduce intraovarian androgen levels. This leads to a reduced sensitivity and expression of granulosa cell-follicle stimulating hormone receptors which result in a less exaggerated response to gonadotropins. Furthermore, it is suggested that Metformin prevents OHSS by controlling vascular permeability through the inhibition of various vasoactive molecules, including VEGF.&lt;br /&gt;
&lt;br /&gt;
'''Avoiding hCG during Luteal Phase Support&lt;br /&gt;
&lt;br /&gt;
Following Controlled Ovarian Stimulation, the steroid levels of E2 and P4 are reduced during the luteal phase due to the negative feedback on the pituitary. This leads to low endogenous LH levels, which consequently reduce endometrial receptivity as well as the luteal phase duration itself. As a result, implantation and pregnancy rates are reduced and early pregnancy loss rates are increased.&amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt; Luteal Phase Support (LPS) serves to combat these adverse events with the use of hCG. However, hCG has been found to increase the risk of OHSS. Alternatively, the use of progesterone has been found to not only halve the risk of OHSS, but also induce similar improvements in pregnancy and miscarriage rates as hCG.&amp;lt;ref name=&amp;quot;PMID26148507&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;26148507&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Secondary Prevention===&lt;br /&gt;
&lt;br /&gt;
Secondary Prevention aims to prevent progression to OHSS once COS has been initiated and the patient has been found to mount an exaggerated response. &amp;lt;ref name=&amp;quot;PMID20416867&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Coasting'''&lt;br /&gt;
&lt;br /&gt;
Coasting is a first-line secondary preventative strategy. It consists of the withdrawal of gonadotrophins when a critical number of follicles and/or E2 concentration is reached. hCG is administered once the E2 concentration reduces to a safe level, before the process of oocyte retrieval commences. This preventative strategy is conducted for a period of less than 3 days in order to avoid compromising IVF outcomes.&lt;br /&gt;
&lt;br /&gt;
'''Cryopreservation'''&lt;br /&gt;
&lt;br /&gt;
Cryopreservation of embryos after oocyte retrieval is another avenue which may avert OHSS progression. The cryopreserved embryos are only reimplanted once the patient's hormone serum levels have normalised. Using oocyte vitrification, crystal formation within embryo tissue is avoided and so cryopreserved embryos have been found to produce better pregnancy rates with a 32% increase, than fresh embryo transfer. Recent studies suggest cryopreservation itself does not reduce OHSS rates, but must be followed by a GnRHa trigger to avert OHSS.&lt;br /&gt;
&lt;br /&gt;
'''Cycle cancellation'''&lt;br /&gt;
&lt;br /&gt;
Cycle cancellation is a guaranteed method to prevent early OHSS whereby hCG is withheld. This is a last resort strategy as it carries the risk of significant psychological distress and financial loss for the patient. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Despite OHSS typically being of iatrogenic origin as a result of ovarian stimulation with gonadotropins, research has been conducted into the potential genetics behind OHSS as many sporadic and familial cases have been observed. '''Mutations''' in the receptor for hormones such as Follicle Simulating Hormone (FSH), Lutenizing Hormone (LH) and hCG have all been targets of OHSS genetics research. Interestingly, they too also arise from a common ancestral gene. &lt;br /&gt;
&lt;br /&gt;
===Follicle Stimulating Hormome===&lt;br /&gt;
&lt;br /&gt;
Dr. Botros Rizk, of the University of South Alabama College of Medicine &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19573286&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, has written extensively regarding the genetics behind OHSS. In particular, he talks about '''FSH receptors''' (FSHR) and their role in the syndrome. He hypothesises that mutations in these receptors could be activating or inactivating, leading to an increased risk of developing OHSS or sterility respectively. Currently, 744 single nucleotide polymorphisms (a type of mutation) have been found in the gene encoding the FSHR, 8 of which are located in its exons (coding regions of the gene). How the ovary responds is resultant on the FSHR genotype. For example, Ser680Asn, a polymorphism in the FSHR gene has been shown to aid in predicting the severity of a woman's OHSS. Ordinarily FSH stimulates the growth of ovarian follicles, however, when mutated, it is stimulated by the hCG resulting in excessive follicle development.&lt;br /&gt;
&lt;br /&gt;
Spontaneous OHSS, OHSS that arises and cannot be attributed to any form of ovarian stimulation or Assisted Reproductive Technology, has been linked to activating mutations in the FSHR &amp;lt;ref name=&amp;quot;PMID23499866&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;23499866&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. This familial disorder is an autosomal dominant one. In most cases the FSHR can be stimulated by the presence of Thyroid Stimulating Hormone (TSH) or hCG, in the absence of FSH (the ligand for FSHR).&lt;br /&gt;
&lt;br /&gt;
===Lutenizing Hormome===&lt;br /&gt;
&lt;br /&gt;
The '''Lutenizing Hormone Receptor''' (LHR) gene in humans is comprised of 11 exons. Animal studies have shown that many primates exhibit a similar gene which is comprised of only 10 exons, however a gene lacking the 10th exon has been identified and termed the type 2 LHR. Expression of the type 2 LHR has been seen in humans. The type 2 LHR, compared to the wild-type LHR appears to be repaired with regard to its function. Defects in the type 2 LHR include a decrease in efficiency of transport to the plasma membrane and irregularities in signal transduction. Inactivating mutations in the LHR have been seen to cause infertility in women as well as amenorrhoea. Activating LHR gene mutations are asymptomatic and are not associated with OHSS in women. &lt;br /&gt;
&lt;br /&gt;
===Bone Morphogenic Protein===&lt;br /&gt;
&lt;br /&gt;
An imporant growth factor, derived from oocytes called '''BMP-15''' (Bone Morphogenic Protein 15) is vital for female fertility. It belongs to the family of growth factors, Transforming Growth Factor β (TGF-β) and is heavily involved in folliculogenesis. It has been found that mutations in the BMP-15 gene caused infertility in female sheep. Conversely, it has also been indicated in enhanced fertility when BMP-15 is present is high amounts in follicular fluid &amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
A case study done by Hanevik ''et. al.'' in 2013 &amp;lt;ref name=&amp;quot;PMID21565556&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21565556&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; found that a Single Nuclear Polymorphism (SNP) in the BMP-15 gene is responsible for a high response to ovarian hyper-stimulation. The aim of the study was to test the effect the SNP had on BMP-15 with regard to high and low responders buy taking blood from 53 high responders, 38 low responders and 100 non-responders (controls) and analysing 5 noted SNP's. Results from their study showed a correlation between a high response to ovarian hyper-stimulation and the BMP-15 9G allele. The article does state however, that further research is required into the molecular effects of SNP's on the function of BMP-15. &lt;br /&gt;
&lt;br /&gt;
===Vascular Endothelial Growth Factor===&lt;br /&gt;
&lt;br /&gt;
'''Vascular endothelial growth factor''' (VEGF) has been indicated as one of the key agents causing vascular permeability and subsequent ascites in OHSS. The gene, which is located on chromosome 12, is made up of 8 exons (coding regions), of which exons 6 and 7 do not always appear due to the exons being spliced out.The splicing of this gene allows for various isoforms of the gene to exist of which VEGF 121 and 165 appear to play a role in angiogenesis. There are two VEGF Receptors, VEGFR-1 and VEGFR-2 that belong to the tyrosine kinase family of receptors (for more information on VEGF see [[Pathophysiology]]). Because of its distinct role in OHSS, it has been targeted as an area for research for potential treatments. The idea is that if the genetic expression of VEGF and its receptors can be controlled, OHSS can be avoided or treated.&amp;lt;ref name=&amp;quot;PMID19573286&amp;quot; /&amp;gt; &lt;br /&gt;
&lt;br /&gt;
A different study by Hanevik ''et. al.'' , &amp;lt;ref name=&amp;quot;PMID22587628&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;22587628&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; done in 2012 involved analysing blood samples from 53 women with OHSS and 100 women without it (controls) and analysing 6 SNP's in the VEGFR2 gene to find any genetic variations. They found a correlation between women with the VEGF +405cc genotype and the development of OHSS indicating women that undergo controlled ovarian hyper-stimulation and posses his genotype, are at an increased risk of developing OHSS. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Effect on the Newborn==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Animal Models==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&amp;lt;div class=&amp;quot;mw-collapsible&amp;quot; data-expandtext=&amp;quot;↓&amp;quot; data-collapsetext=&amp;quot;↑&amp;quot;&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Ascites'''- An accumulation of fluid in the peritoneal cavity with resultant abdominal swelling&lt;br /&gt;
&lt;br /&gt;
'''Cabergoline''' - A dopamine receptor agonist used to treat hormone imbalance.&lt;br /&gt;
&lt;br /&gt;
'''GnRH antagonist''' - Gonadotropin Releasing Hormone - A class of compounds that are similar in terms of the structure of natural Gonadotropin Releasing Hormone but has a antagonistic effect.&lt;br /&gt;
&lt;br /&gt;
'''hCG'''- Human Chorionic Gonadotropin&lt;br /&gt;
&lt;br /&gt;
'''Hemoconcentration'''- An increase in the concentration of circulating red blood cells in response to a decrease in blood plasma volume&lt;br /&gt;
&lt;br /&gt;
'''Hypovolemic'''- A decrease in circulating blood volume &lt;br /&gt;
&lt;br /&gt;
'''Iatrogenic'''- Illness caused as a result of a medical examination or treatment &lt;br /&gt;
&lt;br /&gt;
'''Intravenous fluids''' - Is the infusion of liquid substances directly into a vein.&lt;br /&gt;
&lt;br /&gt;
'''IVF'''- In-vitro Fertilization&lt;br /&gt;
&lt;br /&gt;
'''NSAID'''- Non-steroidal Anti-Inflammatory Drug e.g. Ibuprofen &lt;br /&gt;
&lt;br /&gt;
'''OHSS'''- Ovarian Hyper-stimulation Syndrome&lt;br /&gt;
&lt;br /&gt;
'''FSH''' - Follicle Stimulating Hormone&lt;br /&gt;
&lt;br /&gt;
'''LH''' - Luteinizing Hormone&lt;br /&gt;
&lt;br /&gt;
'''Oliguria'''- Decreased urine output/small amounts of urine produced&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==References==&lt;/div&gt;</summary>
		<author><name>Z3374116</name></author>
	</entry>
</feed>